You are here: Archives / Fink Collection / Max Fink Publications
Sunday, 26.05.2019

Publications

MAX FINK, M.D.
P.O. Box 457
St. James, NY 11780
mafink@attglobal.net
max.fink@stonybrook.edu



1950

1. Subdural hematoma developing during hospitalization. Amer. J. Psychiat.,107:381-383 (with M. Green).

2a. Patterns in perception of simultaneous tests of face and hand. Trans. Amer. Neurol.Ass., 75: 250
(with M.B. Bender and M. Green). (abstract).

1951

2b. …ibid., Arch. Neurol. Psychiat. (Chic.),66: 355-362.

1952

3. The face-hand test as a diagnostic sign of organic mental syndrome. Neurology (Minneap.),2: 46-58
(with M.B. Bender and M. Green).

4. Tactile perceptual tests in the differential diagnosis of psychiatric disorders. J. Hillside Hosp.,1: 21-31 (with M.B. Bender).

5. A clinical evaluation of carotid angiography. Contin Neurol. (Basel), 12: 181-195 (with J.M. Stein).

6a. Exosomesthesia, or displacement of cutaneous sensation into extra­-personal space. Trans. Amer. Neurol. Ass., 77: 260-262 (with M.F. Shapiro and M.B. Bender). (abstract).

6b. …ibid., Arch. Neurol. Psychiat. (Chic.),68: 481-490.

7a. Order of dominance in cutaneous perception. Trans. Amer. Neurol. Ass., 77: 238-240 (with M.B. Bender and M. Green). (abstract).

7b. Patterns of perceptual organization with simultaneous stimuli. Arch. Neurol. Psychiat. (Chic.),72: 233-255 (with M.B. Bender and M. Green), 1954.

1953

8. Perception of simultaneous tactile stimuli in normal children. Neurology (Minneap.), 3: 27-34
(with M. B. Bender).

9. Perception of simultaneous tactile stimuli by mentally defective subjects. J. Nerv. Ment. Dis.,117: 43-49 (with M.B. Bender and M. Green).

10. Spinal fluid findings following cerebral angiography. Neurology (Minneap.),3: 137 (with J.M. Stein).

11. A statistical study of a psychoanalytic hypothesis: absence of a parent as a specific factor determining choice of neurosis. J. Hillside Hosp.,2: 67-71 (with S. Tarachow).

12. Effects of intravenous barbiturate on perception. Trans. Amer. Neurol. Ass., 78: 244-245
(with M.B. Bender, P. Bergman, and M. Nathanson). (abstract).

13. Homosexuality with panic and paranoid states case report. J. Hillside Hosp.,2: 164-190.

1954

14. Standardization of the face-hand test. Neurology (Minneap.),4:211-217 (with M. Green).

1955

15. The “Amytal test” in patients with mental illness. J. Hillside Hosp.,4: 3-13 (with R.L. Kahn and
E.A. Weinstein).

16. Delusional reduplication of parts of body after insulin coma therapy. J. Hillside Hosp.,4: 134-147
(with R.L. Kahn and D. Graubert).

1956

17. Relation of Amobarbital test to clinical improvement in electroshock. Arch. Neurol. Psychiat. (Chic.),
76: 23-29 (with R.L. Kahn and E.A. Weinstein).

18. Evaluation of high dose reserpine therapy for the relief of anxiety. J. Hillside Hosp.,5: 67-77
(with M. Wachspress, A.G. Blumberg,and J.S.A. Miller).

19. Relation of Changes in Memory and Learning to Improvement in Electroshock. Confin. Neurol. (Basel),
16: 88-96 (with H. Korin and S. Kwalwasser).

20. Denial of blindness following cerebral angiography. J. Hillside Hosp., 5: 238-245.

21a. Quantitative studies of slow wave activity following electroshock. Electroenceph. Clin. Neurophysiol.,
8: 158 with R.L. Kahn). (abstract).

21b. Relation of EEG delta activity to behavioral response in electroshock: quantitative serial studies. Arch. Neurol. Psychiat. (Chic.), 78: 516-525, 1957 (with R.L. Kahn).

1957

22a. EEG and clinical response to Megimide. Electroenceph. Clin. Neurophysiol., 9: 180
(with M. Green). (abstract).

22b. Clinical and electroencephalographic effects of Megimide in patients without cerebral disease. Neurology (Minneap),8: 682-685 (with M. Green).

23. A unified theory of the action of physiodynamic therapies. J. Hillside Hosp.,6: 197-206.

24. Perception of embedded figures after induced altered brain function. American Psychologist, 12: 361 (with R.L. Kahn).

25. Social factors in selection of therapy in a voluntary mental hospital. J. Hillside Hosp.,6: 216-228
(with R.L. Kahn and M. Pollack).

26. Role of stimulus intensity in perception of simultaneous cutaneous electrical stimuli. J. Hillside Hosp.,
6: 241-250 (with H. Korin).

Added 2/25/17  Soviet Medical Advances: Importance of making literature available to American scientists. New York Times Letters, 15 Nov 1957, pg 26.

1958

27. Changes in language during electroshock therapy. In P.H. Hoch and J. Zubin (eds.), Psychopathology of Communication. Grune and Stratton, New York, 1958: 126-139 (with R.L. Kahn).

28. Lateral gaze nystagmus as an index of the sedation threshold.Electroenceph. Clin. Neurophysiol.,10:162-163.

29a. Effects of Diethazine on EEG and significance for theory of convulsive therapy. Electroenceph. Clin. Neurophysiol. 10:207-208. (abstract).

29b. Effect of anticholinergic agent, Diethazine, on EEG and behavior: significance for theory of convulsive therapy. Arch. Neurol. Psychiat. (Chic.),80:380-387.

29c. ...ibid.,In J.H. Masserman (ed.), Biological Psychiatry. Grune and Stratton, New York, 1959, 1: 184-194.

30. Experimental studies of the electroshock process. Dis. Nerv. Syst.,19: 113-118 (with R.L. Kahn and
M. Green).

31. Comparative study of Chlorpromazine and insulin coma in the therapy of psychosis. J. Amer. Med. Ass., 166: 1846-1850 (with R. Shaw, G. Gross, and F.S. Coleman).

32. Electroencephalographic correlates of the electroshock process. Dis. Nerv.Syst., 19: 227 (with M. Green). (abstract).

33a. Experimental studies of convulsive and drug therapies in psychiatry: theoretical implications.
Arch. Neurol. Psychiat. (Chic.),80:733-734 (with R.L. Kahn and M.A. Green). (abstract).

33b. Alteration of brain function in therapy. In N.S. Kline (ed.), Psychopharmacology Frontiers.

Little, Brown & Co.,Boston, 1959: 325-332.

34a. Effect of anticholinergic compounds on post-convulsive electroencephalogram and behavior. Electroenceph. Clin. Neurophysiol.,10:776. (abstract).

34b. Effect of anticholinergic compounds on post-convulsive electro­encephalogram and behavior of psychiatric patients. Electroenceph. Clin. Neurophysiol.,1960, 12: 359-369.

1959

35. Effects of diffuse altered brain function on perception. In Proc. XV Int. Congr. Psychol. North Holland, Amsterdam: 238-239 (with R.L. Kahn and H. Korin). (abstract).

36. Psychological factors affecting individual differences in behavioral response to convulsive therapy.
J. Nerv. Ment. Dis.,128: 243-248 (with R.L. Kahn and M. Pollack).

37a. Significance of EEG pattern changes in psychopharmacology. Electroenceph. Clin. Neurophysiol.,11:398. (abstract) .

37b. EEG and behavioral effects of psychopharmacologic agents. In P. B. Bradley, P. Deniker, and
C. Radouco-Thomas (eds.), Neuro-Psychopharmacology. Elsevier, Amsterdam, 1959, 1: 441-446.

38a. Electroencephalographic and behavioral effects of Tofranil. Canad. Psychiat. Assoc.J.,4 Suppl.: 166-171.

38b. …ibid., Electroenceph. Clin. Neurophysiol.,1960, 12: 243-244. (abstract).

39. Relation of tests of altered brain function to behavioral change following induced convulsions. 

In L. van Bogaert and J. Radermecker (eds.), FirstInternational Congress of Neurological Sciences. Pergamon Press, London, 1959, 3: 613-619 (with R.L. Kahn and H. Korin).

40. The Role of set in the perception of simultaneous tactile stimuli. Amer. J. Psychol.,72: 384-392 

(with H. Korin).

41. Personality factors in behavioral responses to electroshock therapy. J. Neuropsychiat.,1: 45-49 

(with R.L. Kahn).

42. Sociopsychologic aspects of psychiatric treatment in a voluntary mental hospital: duration of hospitalization, discharge ratings and diagnosis. Arch. Gen. Psychiat.,1: 565-574 (with R.L. Kahn and 

M. Pollack).
           
1960

43. Efficacy of divided and single dose schedules in insulin coma therapy. Amer. J. Psychiat.,116: 839-840 (with A.G. Blumberg and P. Laderman).

44. Changes in verbal transactions with induced altered brain function.  J. Nerv. Ment. Dis.,130:235-239 (with J. Jaffe and R.L. Kahn).

45. Drug induced changes in interview patterns: linguistic and neurophysiologic indices. In G.J. Sarwer-Foner (ed.), The Dynamics of Psychiatric Drug Therapy. C.C. Thomas, Springfield, IL, 1960: 29-44 

(with J. Jaffe and R.L. Kahn).

46. Social attitude California F Scale and convulsive therapy. J. Nerv. Ment. Dis.,130:187-192 

(with R.L. Kahn and M. Pollack).

47. Figure-ground discrimination after induced altered brain function. Arch. Neurol. (Chic.),2: 547-551 

(with R.L. Kahn and M. Pollack).

48. Prognostic value of Rorschach criteria in clinical response to convulsive therapy. J. Neuropsychiat.,1: 242-245 (with R.L. Kahn).

 1961

49. Modification of psychotherapeutic transactions by altered brain function. Amer. J. Psychother.,15: 46-55 (with J. Jaffe, H. Esecover, R.L. Kahn).

50. Neuropsychologic response patterns of some psychotropic drugs. In E. Rothlin (ed.), Neuro-psychopharmacology. Elsevier, Amsterdam, 1961, 2: 381-384 (with M. Pollack, E. Karp, G. Krauthamer, and D.F. Klein).

51. …ibid., Problems of antagonists to psychotropic drugs, 30-32.

52. Inhalant-induced convulsions. Arch. Gen. Psychiat., 4: 259-266  (with R.L. Kahn, E. Karp, M. Pollack, M.A. Green, B. Alan, H.J. Lefkowits).

53. Behavioral patterns in convulsive therapy. Arch. Gen. Psychiat., 5: 30-36 (with R.L. Kahn).

54. Sociopsychological characteristics of patients who refuse convulsive therapy. J. Nerv. Ment. Dis., 132: l53-l57 (with M. Pollack).

55. EEG techniques in study of psychotropic drugs. Acta of the Internationat. Meeting on the Techniques for the Study of Psychotropic Drugs, Bologna, 1960. Societa Tipografica Modenese, Modena, 1961: 3pp.

56. Withdrawal symptoms following discontinuation of Imipramine therapy. Amer. J. Psychiat., 118: 549-550 (with J.C. Kramer and D.F. Klein).

57. Experimental psychiatric research at Hillside: reviewand prospect. J. Hillside Hosp., 10: 159-169.

58. Prediction of individual patient response to convulsive therapy. VA Cooperative Chemotherapy Studies in Psychiatry, 6: 317-324.

59. Social aspects of psychiatric treatment in three hospitals: methodological problems. VA Cooperative Studies in Psychiatry, 6:202-206 (with M. Pollack, N. Siegel, and R.L. Kahn).

60. Quantitative electroencephalography and human psychopharmacology: I. Frequency spectra and drug action. Med. Exp. (Basel),5:364-369.

1962

61. The critical flicker frequency and EEG alpha: a reliability study. Electroenceph. Clin. Neurophysiol., 14:60-63 (with E. Karp and M. Pollack).

62. The mode of action of convulsive therapy: the neurophysiologic-adaptive view.  J. Neuropsychiat., 3: 231-233.

63.  Disordered perception of simultaneous stimulation of face and hand: a review and theory. In J. Wortis (ed.), Biological­Psychiatry. Plenum Press, Inc., New York, 1962, 4: 362-369 (with M. Pollack).

64. Tachistoscopic perception after induced altered brain function: influence of mental set. J. Nerv. Ment. Dis., 134: 422-430 (with M. Pollack, R.L. Kahn, and E. Karp).

65. Motivation for psychotherapy. Comprehens. Psychiat., 3: 170-173 (with N. Siegel).

66. Psychiatric reaction patterns to Imipramine (Tofranil).  Amer. J. Psychiat., 119: 432-438
(with D.F. Klein).

67. Behavioral reaction patterns with Phenothiazines. Arch. Gen. Psychiat., 7: 449-459 (with D.F. Klein).

68. The disposition of applications for psychotherapy in an out-patient clinic. Social-Casework, 43: 545-547 (with N. Siegel).

69. Social class, diagnosis, and treatment in three psychiatric hospitals. Social-Problems, 10: 191-196
(with N. Siegel, R.L. Kahn, and M. Pollack).

70. Imipramine as an adjunct to Phenothiazine therapy.  Comprehens. Psychiat., 3: 377-380 (with J.C. Kramer and D.F. Klein).

1963

71. EEG and human psychopharmacology. Abstracts of Proceedings of Symposium at Third World Congress of Psychiatry, Montreal, 1961). Electroenceph. Clin. Neurophysiol., 15: 133-137.

72.  Multiple item factors as change measures in psychopharmacology. Psychopharmacologia (Berl.), 4: 43-52 (with D.F. Klein).

73. Quantitative electroencephalography in human psychopharmacology II: drug patterns. In G. Glaser (ed.), EEG and Behavior. Basic Books, Inc., New York, 177-197.

74. Effects of Imipramine and Chlorpromazine on perceptual analytic ability, perceptual responsivity and memory as revealed in Rorschach responses.  J. Nerv. Ment. Dis., 137: 42-50 (with I. Belmont, M. Pollack, and A. Willner).

1964

75. A selected bibliography of electroencephalography in human psychopharmacology, 1951-1962.  Electroenceph. Clin. Neurophysiol., Suppl. 23, 68 pp.

76.  Comparative study of period analysis and frequency analysis of the electroencephalogram.  Electroenceph. Clin. Neurophysiol., 17:454-455. (with N. Burch). (abstract).

77.  Comparative studies of Chlorpromazine and Imipramine I: drug discrimination patterns. In P.B. Bradley, F. Flugel, and P.H. Hoch (eds.), Neuro-Psychopharmacology.  Elsevier, Amsterdam, 3: 370-372

(with M. Pollack, D.F. Klein, A.G. Blumberg, I. Belmont, E. Karp, J.C. Kramer, and A. Willner).

78. Comparative studies of Chlorpromazine and Imipramine II: psychological performance profiles.

In P.B. Bradley, F. Flugel, and P.H. Hoch (eds.), Neuro-Psychopharmacology. Elsevier, Amsterdam, 3: 373-376 (with M. Pollack, E. Karp, I. Belmont and A. Willner).

79. Digital computer analysis of EEG using an IBM 1710 system. Electroenceph. Clin. Neurophysiol., 17: 712 (with D. Shapiro, D. Bridger and T. Itil). (abstract).

1965

80. Clinical efficacy of Chlorpromazine-Procyclidine combination, Imipramine and placebo in depressive disorders. Psychopharmacolgia (Berl.), 7: 27-36 (with D.F. Klein and J. Kramer).

81. Imipramine-induced behavioral disorganization in schizophrenic patients: physiological and psychological correlates. In J. Wortis (ed.), Biological Psychiatry. Plenum Press, Inc., New York, 7: 53-6l (with M. Pollack, D.F. Klein, A. Willner, and A.G. Blumberg).

82a. EEG analyses by digital computer, I: development of IBM 1710 System. Electroenceph. Clin. Neurophysiol., 18: 520 (with T. Itil, D. Shapiro, and D. Bridger). (abstract).

82b. EEG analyses by digital computer, II: relation of pentothal induced changes to resting pattern.  Electroenceph. Clin. Neurophysiol., 18: 520-21 (with T. Itil). (abstract).

83. QuantitativeEEG and human psychopharmacology, III: changes on acute and chronic administration of Chlorpromazine, Imipramine and placebo saline. In W. P. Wilson: Applications of Electro­encephalography in Psychiatry. Duke University Press, Durham, North Carolina, 226-240.

84. Clinical neurophysiology. In D. Bente and P. Bradley (eds.), Neuro-Psychopharmacology, Elsevier, Amsterdam, 4: 64-69.

1966

59b. Sociopsychological aspects of psychiatric treatment in three voluntary hospitals.  A.M.A. Arch. Gen. Psychiat., 14: 20-25 (with R.L. Kahn and N. Siegel).

85. Klinische Untersuchungen und quantitative EEG-daten bei experimentellen Psychosen.  Arzneimittel-Forsch., 16: 237-240 (with T. Itil).

86. Die Anwendung von Digital-Computer Methoden in der Psychopharmakologie.  Arzneimittel-Forsch., 16:297-299 (with T. Itil and D. Shapiro).

87. Trifluperidol in the treatment of psychosis. observations suggestive of anticholinergic activity at higher dosages.  J. New Drugs, 6: 174-181 (with A. Don, M. Stallings, T. Itil and J.M. Holden).

88. Cholinergic mechanisms in mental illness: anticholinergic hallucinogens. In J. Wortis (ed.), Recent Advances in Biological Psychiatry, Plenum Press, Inc., N.Y., 8: 115-119.

89. …ibid., Drug induced or spontaneous psychopathological changes and the relationship to quantitative electroencephalography,8: 303 (with T. Itil and A. Keskiner). (abstract).

90. …ibid., Classification of psychosis by quantitative EEG measures, 8: 305-312 (with T. Itil and D. Clyde).

91. Cholinergic aspects of convulsive therapy. J. Nerv. Ment. Dis., 142: 475-484.

92. The question of dissociation of EEG and behavior with anticholinergic agents. Electroenceph. Clin. Neurophsiol., 21: 41 (with T. Itil). (abstract).

93. Prolonged adverse reactions to LSD in psychotic subjects.  Arch. Gen. Psychiat., 142: 450-454
(with J. Simeon, W. Haque, and T. Itil)

94. Behavior and quantitative EEG changes induced by hallucinogenic drugs. Proc. XVIII Int. Cong. Psychol., (Moscow) I: 224 (with T. Itil). (abstract). 

95. Anticholinergic drug induced delirium experimental modification, quantitative EEG and behavioral correlations.  J. Nerv. Ment. Dis., 143: 492-507 (with T. Itil).

96. Therapeutic studies in therapy resistant schizophrenic patients. Comprehens. Psychiat., 7: 488-493
(with T. Itil and A. Keskiner). 

1967

97. Clinical trial of Navane Thiothixene in schizophrenia. Curr. Ther. Res., 9: 10-16. (with J. Simeon,
A. Keskiner, D. Ponce, T. Itil).

98. Clinical laboratory test standards in newdrug trials. J. Clin. Pharmacol. and New Drugs, 7: 1-8. 
(with J. M. Holden, T. Itil, J. Simeon).

99. Organic treatment of schizophrenia. In Textbook of Psychiatry, A.M. Freedman and H. Kaplan (eds.). Williams and Wilkins, Baltimore, pp. 661-664 (with T. Itil).

100a. …ibid., Computers and psychiatry,Chapter 5.2, pp. 232-238.

100b. …ibid., Human Behavior: Biological, Psychological, and Sociological, A.M. Freedman and H. Kaplan (eds.), Atheneum, 1972, 450-460.

101a. Quantitative analysis of the electroencephalogram by digital computer methods. III. Applications to psychopharmacology. VII IBM Medical Symposium, Poughkeepsie, IBM Press, pp. 263-290.

101b . …ibid., Computers and Electronic Devices in Psychiatry, N.S. Kline and E. Laska (eds.), Grune and Stratton, 109-123, 1968 (with D.M. Shapiro, C. Hickman and T. Itil).

102. Through a mirror darkly. Review of Psychopathology of Perception. P.H. Hoch and J. Zubin (eds.), N.Y., Grune and Stratton. Contemp. Psychol., 11: 536-538.

103. Altered sensitivity to centrally active drugs following lobotomy. In. J. Wortis (ed.), Biological Psychiatry, Plenum Press, Inc. N.Y., 9: 157-170 (with T. Itil, J. Holden, A. Keskiner).

104. Effect of Sulthiame in schizophrenic patients.  Proc. First Init. Cong. Acad. Psychosom. Med., E. Dunlop (ed.) pp. 185-194, Amsterdam, Excerpta Med. Fdn. (with T. Itil, A. Keskiner).

105. Digital computer analysis of the human EEG in psychiatric research. Comprehens. Psychiat., 8: 521-538 (with T. Itil and D. Shapiro).

106a. EEG and behavioral aspects of the interaction of anticholinergic hallucinogens with centrally active compounds. Anticholinergic Drugs and Brain Functions in Animals and Man, P. Bradley and M. Fink (eds.), Elsevier, Amsterdam, pp. 149-168 (with T. Itil).

106b. Anticholinergic hallucinogens and their interaction with centrally active drugs. Neuropsychopharmacology, H.Brill (ed.), Excerpta Medica, Amsterdam, pp. 381 (with T. Itil).

107. Anticholinergic drugs and brain function in animals and man. Neuro-psychopharmacology, H. Brill (ed.), Excerpta Medica, Elsevier, Amsterdam, pp. 374-390.

108. Treatment of chronic psychotic patients with combined medications. Neuropsychopharmacology,
H. Brill (ed.), Excerpta Medica, Amsterdam, pp. 1016-1020 (with T. Itil, J. Holden, D. Shapiro, A. Keskiner).

109. EEG Patterns with combined drug treatments in psychotic patients. Turk J. Electroenceph. Clin. Neurophysiol, 1: 1-9 (with T. Itil, G. Ulett).

110. Anticholinergic Drugs and Brain Functions in Animals and Man, P. Bradley and M. Fink (eds.), Progress in Brain Research, Vol.28, Elsevier, Amsterdam, pp. 375, 1965.

111. Brain, behavior and anticholinergic drugs. Anticholinergic Drugs, and Brain Functions in Animals and Man, P. Bradley and M. Fink (eds.), Elsevier, Amsterdam, pp. xii-xvi.

112. Quantitative EEG: A new dimension in psychopharmacology. Proceedings IV World Congress Psychiat., Excerpta Med. Fdn., Amsterdam, pp. 338-339.

113a. The differentiation of tranquillizers by quantitative EEG. Electroenceph. Clin. Neurophysiol. 24 (withT. Itil, D. Shapiro, C. Hickman, and N. Kiremitci). (abstract).

113b. Quantitative EEG Studies of Chlordiazepoxide, Chlorpromazine and Imipramine in volunteer and schizophrenic subjects. Psychopharmacology of the Normal Human, W. Evans and N.S. Kline (eds.),
C.C. Thomas, Springfield, Chapter 9, pp. 219-238, 1969 (with T. Itil, D. Shapiro, N. Kiremitci, C. Hickman).

114. On-line computer classification of electronencephalographic sleep stages. Psychophysiology 4: 366
(with T. Itil, D. Shapiro, C. Hickman, N. Kiremitci and J.M.C. Holden). (abstract).

115. Cyclazocine and Methadone in narcotic addition. J.A.M.A., 202:191-194 (with A.M. Freedman,
R. Sharoff and A. Zaks).

116a. Social class and prognosis of schizophrenia. Turk. Noro-Psikiyatri Arsivi, 4: 1-12. (with N. Freilich,
T. Itil).

116b. …ibid., The influence of family structure and attitudes on the course and prognosis of schizophrenia, 5: 1-10, 1968 (with N. Freilich, T. Itil, J. M. Holden).

1968

117. Neurophysiological Response Strategies in the Classification of Mental Illness in The Role of Methodology of Classification in Psychiatry and Psychopathology, Katz, M.M., Cole, J.O., and Barton,
W.E. (eds.), Washington, DC Govt. Printing Office, pp. 535-540.

118. Long acting Phenothiazine (Fluphenazine Decanoate) in the treatment of psychosis.  Arch.Gen. Psychiat., 18: 477-481 (with A. Keskiner, J.Simeon, and T.M. Itil).

119. Clinical Studies of Cyclazocine in the Treatment of Narcotic Addiction.  Amer.J. Psychiat., 124: 1499-1504 (with A.M. Freedman, R. Sharoff, and A. Zaks).

120. Naloxone in heroin dependence. Clin. Pharm. Therap., 9: 568-577 (with A. Zaks, R. Sharoff, A. Mora, A. Bruner, S. Levit, A.M. Freedman).

121. Basic concepts and use of Cyclazocine in the treatment of narcotic addiction. Brit.J. Addict., 63: 59-69 (with A.M. Freedman).

122. Differentiation of psychotropic drugs by quantitative EEG analysis. Agressologie, 9: 267-280, 1968 (with T. Itil, D. Shapiro).

123. Thioridazine and Chlordiazepoxide, alone or combined, in the treatment of chronic schizophrenia.
Comp. Psychiat., 9: 633-643 (with J. Holden, T. Itil, A. Keskiner).

124. EEG classification of psychoactive compounds in man: review and theory of behavioral associations. Psychopharmacology: A Review of Progress, 1957-1967: D. Efron, J. Cole, J. Levine and J.B. Wittenborn (eds.): U.S. Govt. Printing Office, Washington, DC, pp. 497-507. 

1969

127. The human electroencephalogram: index of clinical activity of new psychoactive agents. Mod. Prob. Pharmacopsychiat., 2: 106-110.

128. EEG and human psychopharmacology. Ann. Rev. Pharmacol., 9: 241-258.

129. Psychoactive drugs and the alert human EEG. Pakistan Medical Review 3: 29-40.

130. Digital computer classifications of EEG sleep states. Electroenceph. Clin. Neurophysiol. 27: 76-83
(with T. Itil, D.M. Shapiro, D. Kassebaum).

131. Intravenous Diacetylmorphine (Heroin) in studies of opiate dependence. Dis. Nerv. Syst. Suppl., 30:89-92 (with A. Zaks, A. Bruner, A. Freedman).

132. High dose Chlordiazepoxide therapy of anxiety. Curr.Therap. Res., 11:9-14 (with M. Taylor, M. Spero, J. Simeon).

133. Liquid Butaperazine response in the treatment of chronic psychosis in a mental health clinic. Curr.Therap. Res. 11: 57-63 (with G. Clare, J. Simeon, ).

134. High dose Tybamate therapy of heroin dependence. J. Clin. Pharmacol. New Drugs. 9: 232-238 

(with F. Veress, V. Major, A. Freedman).

135. Narcotic antagonists and substitutes in opiate dependence. The Present Status of Psychotropic Drugs. 

A. Cerletti and F.J. Bove(eds.), Excerpta Med. Fdn., Amsterdam, 428-431 (with A. Freedman, A. Zaks,
R. Sharoff, R. Resnick).

136. Clinical and EEG studies of Doxepin: an interim report. Psychosomatics, 10:14-17 (with J. Simeon,

M. Spero).

137. High and very high dose Fluphenazine in the treatment of chronic psychosis. In The Present Status of Psychotropic Drugs, A. Cerletti and F. J. Bove (eds.), Excerpta Med. Fdn., Amsterdam, 495-497 

(with N. Polvan, V. Yagcioglu, T. Itil).

138a. EEG Patterns as an index of clinical activity of psychoactive drugs. Electroenceph. Clin. Neurophysiol., 27: 710 (with D.M. Shapiro). (abstract).

138b. Drugs, EEG and behavior. Drugs and the Brain, P.Black (Ed.), Baltimore, Johns Hopkins Press, Chapter X, pp. 149-160.

139. Electroencephalograms, mental state and psychoactive drugs. Pharmacol. for Physicians. 

W.B. Saunders, Philadelphia, 3 (5): 1-5.

140. Electroencephalographic effects of Trifluperidol. Dis. Nerv. Syst., 30:524-540 (with T. Itil).

141. EEG Patterns of Cyclazocine, a narcotic antagonist. In Neurophysiological and Behavioral Aspects of Psychotropic Drugs, A. Karczmar and W.P. Koella (eds.), C.C. Thomas, Philadelphia, Chapter 4, pp. 62-71 (with T. Itil, A. Zaks, A.M. Freedman).

142. Neuropharmacological analysis of agonistic actions of cyclazocine in rabbits. Biol. Psychiat., 1:217-330(withR.P. White, W.G. Drew).

143. Anxiety precipitated by lactate. New Eng. J. Med., 281:1429(with M.A. Taylor and J. Volavka). (letter).

1970

144. Antagonists in the treatment of opiate dependence. In Modern Trends in Drug Dependence and Alcoholism, R.V. Phillipson, (ed.), Butterworth, London, pp. 49-59 (with A.M. Freedman).

145. Clinical antidepressant activity of Cyclazocine: a narcotic antagonist. Clin. Pharmacol. Therap., 11: 41-48 (with J. Simeon, T. Itil, and A.M. Freedman).

146. A Cyclazocine typology in opiate dependence. Amer. J. Psychiat., 126: 1256-1260 (with R. Resnick, A.M. Freedman).

147. d-Cycloserine therapy of psychosis by symptom provocation. Comprehens.Psychiat. 11: 80-88
(with J. Simeon, T. Itil, D. Ponce).

148. A comparison of Doxepin and Chloridiazepoxide in the therapy of anxiety. Curr.Therap. Resch., 4: 201-211 (with J. Simeon, M. Spero, O. Nikolovski).

149. Depot Fluphenazine facilitation of treatment of psychosis. In Changing Patterns in Psychiatric Care, T. Rothman (ed.), Crown, N.Y., 176-185 (with J.Simeon, A. Keskiner, T.M. Itil).

150. Narcotic antagonists in opiate dependence. Science, 169: 1005-1006.

151a. Blockade with Methadone, Cyclazocine and Naloxone. Int. J. Addictions, 5: 507-515
(with A.M. Freedman, A. Zaks, R. Resnick).

151b. …ibid., In Einstein, S. Methadone Maintenance, New York, M. Dekker, 161-170, 1971.

152a. Treatment of heroin dependence with opiate antagonists. In Masserman, J. (ed.), Current Psychiatric Therapies, Grune and Stratton, N.Y., 161-170 (with A. Zaks, R. Resnick and A.M. Freedman).

152b. …ibid.,In R.M. Suinn and R.G. Weigl (eds.): Innovative Medical Psychiatric Therapies. Baltimore, University Park Press, 51-60, 1976.

153. Electrographic effects of Diacetylmorphine Heroin and Naloxone in man. Neuropharm., 9: 587-593 (with J. Vo1avka, A. Zaks, J. Roubicek).

154. Technology in psychiatric research. In S. Merlis (Ed.): Non-Scientific Constraints in Medical Research, Raven Press, New York, pp. 91-96.

155a. Lateralized EEG changes after induced convulsions. Electroenceph. Clin. Neurophysiol., 29: 324
(with J. Roubicek, J. Volavka, R. Abrams). (abstract).

155b. Lateralized EEG changes after unilateral and bilateral electroconvulsive therapy. Dis. Nerv. Syst., 31 (11) Suppl.:28-33 (with R. Abrams, J. Volavka, J. Roubicek, R. Dornbush).

1971

156. Depot Fluphenazine in the treatment of psychosis in a community mental health clinic. Dis. Nerv. Syst., 31 (9) Suppl.: 28-3l (with L. Bucci, M. Fuchs, J. Simeon).

157. Long-acting depot Phenothiazines in emergency and maintenance therapy of psychosis. In The Role of Drugs in Community Psychiatry, C. Shagass (ed.), Karger, Basel. Mod. Probl. Pharmacopsychiat., 6: 78-82.

158. Memory changes after unilateral and bilateral convulsive therapy. Brit. J. Psychiat., 119: 75-78 

(with R. Dornbush, R. Abrams).

159. Naloxone treatment of opiate dependence.  JAMA, 215: 2108-2110 (with A. Zaks, T. Jones, 

A.M. Freedman).

160. Opiate antagonists in the treatment of Heroin dependence in man. In Narcotic Drugs, Biochemical Pharmacology, Clouet, D. (ed.), Plenum Publ. Co., New York, pp. 468-477 (with A. Zaks, R. Resnick, and
A. M. Freedman).

161. …ibid., Electrophysiological Studies of Opiates and Antagonists in Man, pp. 452-467 (with A. Zaks,

J. Volavka. J. Roubicek).

162a. A rational therapy of opiate dependence: narcotic antagonists. Amer. J. Nursing, 71: 1359-1363 

(with A.M. Freedman, A. Zaks, R. Resnick).

162b.…ibid.,In The Nurse in Community Mental Health, E. P. Lewis and M. H. Browning (eds.), New York, Amer. J. Nursing Co., 283-293, 1972.

162c. …ibid., J. Psychedelic Drugs, 4: 157-161.

163. Narcotic antagonists in the treatment of opiate dependence. Int. Z. Klin. Pharm. Therap. u. Tox., 4: 455-458 (with A. Zaks, R. Resnick, A.M. Freedman).

164. Toward a rational theory of behavior. Career Directions in Psychiatry; 1: 22-29.

165. Computer Aided Interactive Psychiatric Diagnosis Programs. New York, Biodata, Inc., 75 pp.

(with D. M. Shapiro, S. Feldstein).

166a. Marijuana, memory and perception. Amer. J. Psychiat. 128:194-198 (with R. Dornbush, 

A.M. Freedman).

166b. …ibid.,In E.L. Abel (ed.): Marijuana, Memory and Perception. New York, MSS Information Corp., 23-26, 1973.

167. Marijuana, EEG and behavior. In Marijuana: Chemistry, Pharmacology, and Patterns of Social Use. 

A. Singer and S. Yolles (eds.), Ann. N.Y. Acad. Sci., 191: 206-215 (with J. Volavka, R. Dornbush,
S. Feldstein, G. Clare, A. Zaks, A. Freedman).

168. Cyclazocine therapy of opiate dependence: a progress report. Comprehens. Psychiat., 12: 491-502 (with R. Resnick, A.M. Freedman).

169a. EEG profile analysis for psychopharmacology: a progress report. Electroenceph. Clin. Neurophysiol. 31: 105 (with D.M. Shapiro). (abstract).

169b. Discussion, quantitative EEG. Clin. Electroenceph.,2: 116 (letter).

170. Evidence for a characteristic EEG frequency response to Thiopental. Electroenceph. Clin. Neurophysiol. 31: 149-153 (with J. Schwartz, S. Feldstein, D.M. Shapiro, and T. Itil).

171. EEG profiles of Fenfluramine, Amobarbital and Dextroamphetsmine in normal volunteers. Psychopharmacologia Berl. 22: 369-383 (with D.M. Shapiro and T.M. Itil).

172. Drugs and cerebral function, W.C. Smith (ed.), Book review, Electroenceph. Clin. Neurophysiol.,31: 195.

173. Duration of methadone induced cross-tolerance to heroin. Br.J. Addict., 66:205-208 (with A. Zaks, A.M. Freedman).

174. An author seduced? Book review, Seduction, A Conceptual Model in the Drug Dependencies and Other Contagious Social Ills, P. Blachly. Contemp. Psychol., 16: 721.

1972

175. Convulsive Therapy (ed.). Seminars in Psychiatry 4: 1. Grune & Stratton, Inc., New York, 70 pp.

176. The therapeutic process in induced convulsions ECT. Seminars in Psychiatry, 4: 39-46.

177. Answers to questions about ECT. Seminars in Psychiatry, 4: 33-38 (with R. Abrams).

178. CNS Effects of convulsive therapy: significance for a theory of depressive psychosis. In J. Zubin and  F. Freyhan (eds.): Disorders of Mood, John Hopkins, Baltimore, pp. 93-112.

179a. EEG and clinical change after bilateral and unilateral electroconvulsive Therapy. Electroenceph. Clin. Neurophysiol., 32: 631-639 (with J. Volavka, S. Feldstein, R. Abrams).

179b. …ibid.,32: 251-252. (abstract).

180. Clinical experiences with multiple electroconvulsive treatments. Comprehens. Psychiat., 13:115-121 (with R. Abrams).

181. Unilateral and bilateral ECT: effects on depression, memory and the electroencephalogram. Arch. Gen. Psychiat. 27: 88-94 (with R. Abrams, R.L. Dornbush, S. Feldstein, J. Volavka, J. Roubicek).

182a. A rational therapy of opiate dependence: narcotic antagonists. In C.J.D. Zarafonetis (ed.), 

Drug Abuse: Proceedings of the International Conference, Lea & Febiger, Philadelphia, 171-176.

182b. …ibid.,Discussion,177-188.

183. Clinical status of the narcotic antagonists in opiate dependence. In H. Kosterlitz, H.O.J. Collier, and J. Villareal (eds.): Agonist and Antagonist Actions of Narcotic Analgesic Drugs, London, MacMillan, pp. 266-276 (with A. Freedman, R. Resnick, and A. Zaks).

184. Opiate dependence: treatment and prophylaxis. In H.M. van Praag (ed.): Biochemical and Pharmacologic Aspects of Dependence and Reports on Marijuana Research, Amsterdam, Ervin F. Bohn, pp. 85-99.

185. …ibid.,Cannabis psychosis,194-204 (with A.M. Freedman).

186. Selective drug therapies in clinical psychiatry: neuroleptic, anxiolytic, and antimanic Agents. In Treating Mental Illness: Aspects of Modern Therapy, A. M. Freedman and H. Kaplan, (eds.), New York, Atheneum, pp. 287-309 (with R. Abrams).

187. Levomethadyl in maintenance treatment of opiate dependence.  JAMA, 220:811-813 (with A. Zaks, A.M. Freedman).

188. Treatment and prevention of opiate dependence with narcotic antagonists. Contemp. Drug Probl. 1: 245-262.

189. EEG effects of drug of dependence. In S.J. Mule and H. Brill (eds.). Clinical and Biological Aspects of Drug Dependence, Cleveland, Ohio, Chemical Rubber Co., 379-387.

190. EEG indices of CNS bioavailability of psychoactive drugs. Electroenceph. Clin. Neurophysiol.,33: 246-247 (with D. M. Shapiro). (abstract).

191. Clinical evaluation of GP-41299: an antianxiety agent of the Doxepin type. Arzneimittel-Forschung, 22: 1903-1905 (with P. Gaztanaga, R. Abrams, J. Simeon, T. Jones).

192. Heroin maintenance. JAMA, 221: 602. (letter).

193. Heroin maintenance. Contemp. Drug. Probl., 1: 875-877.

194. Effects of delta-nine-tetrahydrocannabinol on EEG, heart rate, and mood. Electroenceph. Clin. Neurophysiol. 33: 453 (with J. Volavka, R. Dornbush, S. Feldstein). (abstract).

195. 21-day administration of marijuana in male volunteers. In M. F. Lewis (ed.): Current Research in Marijuana, pp. 115-128, New York, Academic Press (with R.L. Dornbush, G. Clare, A. Zaks, P. Crown, 

J. Volavka).

1973

196. Quantitative EEG classification of psychoactive drugs in Man. In U.J. Jovanovic (ed.), The Nature of Sleep, Stuttgart, G. Fisher, pp. 76-78.

197. Methadone relatives and substitutes. J.A.M.A., 223: 80. (letter).

198. The electroencephalogram in clinical psychiatry. In J. Mendels (ed.): Biological Psychiatry,
J. B. Lippincott, N.Y. pp. 33l-344.

199. EEG seizure patterns during multiple unilateral and bilateral ECT. Comprehens. Psychiat., 14: 25-28 (with R. Abrams, J. Volavka).

200. Prediction of clinical response to ECT.  Brit. J. Psychiatry, 122:457-461 (with R. Abrams, S. Feldstein).

201. Heroin maintenance, panel discussion. Contemp. Drug. Probl., 2: 165-200.

202. Drugs, EEG, and behaviour: EEG profiles and bioavailability measures for clinical psychopharmacology. Electroenceph. clin. Neurophysiol., 34: 754. (abstract).

203. EEG, heart rate and mood change “high” after cannabis. Psychopharmacologia, 32:11-25 

(with J. Volavka, P. Crown, R. Dornbush, S. Feldstein).

204. Psychological differentiation and the response of opiate ad­dicts to pharmacological treatment. Brit. J. Addic., 68: 151-157 (with S. Feldstein, P. Chester).

205. Narcotic antagonists. In National Commission on Marijuana and Drug Abuse, Drug Use in America: Probtem in Perspective, Washington, DC, U.S. Government Printing Office, Appendix, IV: 143-157.

206. Levomethadyl Acetate: prolonged duration of opioid effects, including cross-tolerance to heroin, in man. J.A.M.A., 226: 316-318 (with R. Levine, A. Zaks, A., A.M. Freedman).

207. Levomethadyl (LAAM): a long-acting substitute for methadone in maintenance therapy of opiate dependence. In J. Masser­man (ed.), Current Psychiatric Therapies, XIII:151-155. New York, Grune & Stratton.

208. How shocking is shock therapy? Editorial, Biological Psy­chiatry, 7:79-80.

209. Drug models in schizophrenia. In J. O. Cole, A. M. Freedman, and A. J. Friedhoff (eds.), Psychopathology and Psychopharmacology, Baltimore, Johns Hopkins Press, 1973, pp. 108-111.

210. Effects of cannabis on human EEG and heart rate: evidence of tolerance development on chronic use. 

In T.A. Ban, et al. (eds.), Psychopharmacology, Sexual Disorders, and Drug Abuse. Prague, Avicenum, pp. 703-704.

211. Questions in Cyclazocine therapy of opiate dependence. In S. Fisher and A. M. Freedman (eds.), Opiate Addiction: Origins and Treatment. Washington, DC, V. H. Winston and Sons, pp. 203-210.

1974

212. Psychobiology of Convulsive Therapy. Washington, DC, V.H. Winston and Sons (with S. Kety, 

J.McGaugh, and T. Williams (eds.), 312 pp.

213. …ibid.,Induced seizures and human behavior,pp. 1-18.

214. …ibid.,Clinical progress in convulsive therapy, pp. 271-278.

215. EEG applications in psychopharmacology. In M. Gordon (ed.), Psychopharmacological Agents Vol. III). Academic Press, NewYork, pp. 159-174.

216. Simultaneous tactile perception in patients with conversion sensory deficits. J. Mt. Sinai Hosp., 41:141-143 (with M.A. Green).

217. High dose Cyclazocine therapy of opiate dependence. Amer. J. Psychiat. 131: 595-597 (with R. Resnick, A.M. Freedman).

218. Psychoactive drugs, brain function, and human behavior. Proc. World CongressPsychiatry, Amsterdam, Excerpta Medica, pp. 747-750.

219a. Brain function, verbal behavior, and psychotherapy. Comprehensive Psychiatry, 15: 257-266.

219b.  …ibid.,In R. Spitzer and D.F. Klein (eds.): Evaluation of Psychological Therapies. Baltimore, Johns Hopkins Press, 1976, pp. 74-88.

220. Induced seizures. Book review: Neurochemistry of Cerebral Electroshock, W.B. Essman. Science, 184: 789.

221. Book review: International Rev. Neurobiology, Vol. 15.Electro­enceph. Clin. Neurophysiol. 36: 557-558, 1974.

222. Short-term effects of heroin on Man. Arch. Gen. Psychiat. 30:677-684(withJ. Volavka, R. Levine, 

S. Feldstein).

223. EEG and task performance after heroin in post-addicts. Electro­enceph. Clin. Neurophysiol. 37:195-196  (with J.Volavka, R. Levine, M. Komlosi). (abstract).

224. EEG profiles and bioavailability measures of psychoactive drugs. In T. Itil (ed.): Psychotropic Drugs and the Human EEG. Modern Problems in Pharmacopsychiatry, Basel, S. Karger, pp. 76-98.

225. Polypeptide influences on attention, memory, and anxiety in man. Pharmacol. Biochem. and Behavior, 2: 663-668 (with L. Miller, A. Kastin, C.A. Sandman, W.T. Van Veer).

226. Psychiatric diagnosis:  phenotypic or pathophysiologic? Editorial. Biological Psychiatry 9: 227-229.

227. Cerebral electrometry in phase I assessment of psychoactive drugs.  In W.B. Essman and L.Valzelli (eds.): Current Developments in Psychopharmacology, New York, Spectrum Publn., pp. 301-316.

228. Electrophysiologic measures for phase I psychopharmacology in man.  In G. McMahon (ed.): Principles and Techniques of Human Research and Therapeutics, vol. VIII: Psychopharmacological Agents, Mt. Kisco, N.Y., Futura Publishing, pp. 19-30.

229. Marijuana, hashish, and Tetrahydrocannabinol-delta-9: effects on EEG, heart rate, and Mood. J. Psycho. Res.10: 159(with J. Volavka, P. Crown, R. Dornbush). (abstract).

1975

230. Narcotic antagonist therapy of opiate dependence. In R.W. Richter (ed.): Medical Aspects of Drug Abuse, New York: Harper and Row, pp. 160-166.

231. Public hysteria and medical practice.  Letter.  JAMA 232: 1126, 1975 (with L. Koran, M.G. Miller).

232. New strategies of psychotropic drug evaluation. In T. Vossenaar (ed.): Proceedings of a Symposium on Depressive Illness. Amsterdam. Excerpta Medica, pp.44-54.

233. Clinical evaluation of narcotic antagonism in man. In S. Ehrenpreis and M. Neidle (eds.): Methods in Narcotics Research. New York, M. Dekker, pp. 337-346.

234. Book review: Psychotropic Drugs and the Human EEG (eds.T.M. Itil, S. Karger),Basel, 1974. Comprehensive Psychiatry 16: 499-500.

235. Fenmetozole DH-524: Euphoriant classified by cerebral electrometry Curr. Therap. Res. 18: 590-596 (with P. Irwin).

236. Prediction of clinical activity of drugs in man. In Sudilovsky A., Gershon, S. and Beer, B. (eds.) Predictiveness in Psychopharmacology:Preclinical and Clinical Correlations. New York, Raven Press, 

pp. 65-87.

237. …ibid., EEG classification of a novel anorexigenic: PRF-36-CL, comparison with placebo, Dextroamphetamine, and Fenfluramine, 89-103 (with P. Irwin, and P. Sibony).

238. Cerebral electrometry: quantitative EEG applied to human psychopharm­acology. In H. Kunkel and 

G. Dolce (eds.): CEAN - Computerized EEG Analysis. Stuttgart, G. Fischer, 271-288.

239. The effects of extreme high dosage Fluphenazine on resistant schizophrenics in two different countries. In T.M. Itil (ed.): Transcultural Neuropsychopharmacology. Istanbul, Bozak Press, 95-100 (with T. Itil, 

N.O. Polvan).

1976

240. Chronic hashish use and mental disorder. Am. J. Psychiat. 133: 225-227 (with C. Stefanis, A. Liakos, 

J. Boulougouris, A.M. Freedman).

241a. Quantitative EEG studies of marijuana, delta-nine-Tetrahydrocannabinol, and hashish in man. 

In M.C. Braude and S. Szara (eds.): The Pharmacology of Marijuana. New York, Raven Press, 383-391
(with J. Volavka, C.P. Panayioutopolis, and C. Stefanis).

241b. …ibid., Electroenceph. Clin. Neurophysiol. 42: 430, 1977. (abstract).

242. Controlled clinical and quantitative EEG Studies of Triflubazam (ORF-8063) in patients with anxiety. Curr.Therap. Res. 19: 307-315 (with T. Itil, S. Akpinar, N. Polvan, M. Huque, and K. Sungerbey).

243. Antipsychiatrists and ECT. (letter). Brit. Med. J. 1: 280, Jan 31, 1976.

244. Concentration of 5-Hydroxyindoleacetic Acid, Homovanillic Acid, and Tryptophan in the cerebrospinal fluid of depressed patients before and after ECT. Biol. Psychiat. 11: 85-90 (with R. Abrams, W.B. Essman, M.A. Taylor).

245. Book review: LSD: A Total Study, S. Sankar. Westbury, New York, PJD Publications, 1975. Amer. J. Psychiat 133: 593-594.

246. Book review: Safeguarding Psychiatric Privacy, E.M. Laska and R. Blank (eds.), New York, John Wiley & Sons, 1975, Amer. J. Psychiat. 133: 726-727.

247. Pharmacokinetic analysis of quantitative EEG data. In Rationality of Drug Development. Amsterdam, Excerpta Medica #383, 177-180 (with P. Irwin and M. Gastpar).

248. Relation of EEG to blood levels of psychoactive drugs. In L. Gottschalk and S. Merlis (eds.): Pharmacokinetics, Blood Levels, and Clinical Response. New York, Spectrum Publications, 243-250 

(with P. Irwin).

249. Blood levels and EEG effects of Diazepam and Bromazepam. Clin. Pharm. Therap. 20: 184-191 

(with P. Irwin, R. Weinfeld, M. Schwartz, A. Conney).

250a. EEG and Blood Level Correlations for Psychoactive Drugs. In M. Matejcek and G.K. Schenk (eds.): Quantitative Analyses of EEG.  Konstanz, Switzerland, AEG Telefunken, 119-126 (with P. Irwin).

250b. Electroencephalographic measures for pharmacodynamic analysis of psychoactive drugs in Man. 

In P. Deniker, C. Radouco-Thomas, and A. Villeneuve (eds.): Neuropsychopharmacology. Oxford, England, Pergamon Press, 1203-1207, 1978.

251. An empirical comparison of three EEG digital conversion techniques. In M. Matejcek and G.K. Schenk (eds.): Quantitative Analysis of EEG. Konstanz, Switzerland, AEG Telefunken, 379-394 (with P. Irwin).

252. Chronic Cannabis Use. Edited by R.L. Dornbush, A.M. Freedman and M. Fink, Annals N.Y.Academy of Sciences, 282: 430 pp.

253. Effects of acute and chronic inhalation of hashish, marijuana, and THC-delta-9 on brain electrical activity in man: evidence for tissue tolerance. In R. Dornbush, A. Freedman and M. Fink (eds.): Chronic Cannabis Use. Annals N.Y. Academy of Sciences 282: 387-398.

254. Summary. Chronic cannabis use. Annals N. Y.Academy of Sciences 282: 427-430.

255a. EEG and task performance after ACTH 4-10 in man. Neuropsychobiology 2: 293-290 

(with W.Sannita, P. Irwin).

255b. EEG and behavioral effects of ACTH 4-10 in normal volunteers. Electro­enceph. Clin. Neurophysiol. 50:2-3, 1980 (with W. Sannita,P. Irwin). (abstract).

1977

256. CNS sequellae of EST: risks of therapy and their prophylaxis. In C. Shagass, S. Gershon and 

A. Friedhoff (eds.): Psychopathology and Brain Dysfunction. New York, Raven Press, 223-239.

257. EST: a special case in pharmacotherapy. In W.E. Fann, I. Karacen, A.D. Pokorny and R.C. Williams (eds.): Phenomenology and Treatment of Depression. New York, Spectrum Publications, 285-294.

258. The treatment of narcotic poisoning. In H.F. Conn (ed.): Current Therapy, 1977. Philadelphia, 

W.B. Saunders,894-895 (with A. Zaks).

259. Hypothalamic peptides and brain function. In E. Usdin, D. Hamburg, and J. Barchas (eds.) Neuroregulators and Psychiatric Disorders. New York, Oxford Press, 296-298.

260. Hashish:A Study of Long-Term Use. C. Stefanis, R. Dornbush, and M. Fink (eds.). New York, 

Raven Press, 181 pp.

261. …ibid.,Medical studies in long-term hashish users. II. Clinical electroencephalography and echoencephalography, 59-62(withC.P. Panayiotopoulos, J. Volavka, C. Stefanis).

262. …ibid.,Acute EEG effects of cannabis preparations in long-term users, 79-90 (with J. Volavka, 

C.P. Panayiotopoulos).

263. …ibid.,Study of long-term hashish users in Greece: Summary and Discussion,151-158.

264. Book review: Marihuana Chemistry, Biochemistry, and Cellular Effects. G.C. Nahas, W.D.M. Paton, and J.E. Idanpaan-Heikkila (eds.). New York, Springer-Verlag, 1976. Quart. Rev. Biol. 52:236.

265. Quantitative EEG analysis and psychopharmacology. In Remond, A. (ed.): EEG Informatics. 

A Didactic Review of Methods and Applications of EEG Data Processing. Amsterdam, Elsevier, 301-308.

266. EEG, blood level, and behavioral effects of the antidepressant Mianserin (Org GB 94). Psychopharmacologia 54: 249-254 (with P. Irwin, M. Gastpar, and H. de Ridder).

267. Myths of “shock therapy.” Amer. J. Psychiat. 134:991-996.

1978

268. Comments on report by P. Simon.  In P. Deniker, C. Radouco-Thomas,and A. Villeneuve (eds.): Neuropsychopharmacology. Oxford England, Pergamon Press, 215-217.

269. Psychoactive drugs and the waking EEG. In M.A. Lipton, A. DiMascio, and K.F. Killam (eds.): Psychopharmacology: A Generation of Progress. NewYork, Raven Press, 691-698.

270. EEG response strategies in psychiatric diagnosis. In Spitzer, R. and D.F. Klein (eds.): Critical Issues in Psychiatric Diagnosis. New York, Raven Press, 253-263.

271. EEG study of Mianserin (GB-94) in depressed patients. Brit. J. Clin. Pharmacol. 5 Supplement (1): 43S-49S (with P. Irwin).

272. Sieben jahre klinische erfahrung mit opiat-antagonisten bei Opiatabhangigkeit. In W.F. Biniek (ed.): Drogenabhangigkeit. Darmstadt, Wissenschaftliche Buchgesellschaft, 422-431.

273. Efficacy and safety of induced seizures (EST) in man. Comprehens. Psychiat. 19: 1-18.

274. ECT in metropolitan New York hospitals: A survey of practice 1975-1976. Amer. J. Psychiat. 135: 479-482 (with G.M. Asnis, S. Saferstein).

275. Is EST a useful therapy of schizophrenia? In J.P. Brady and H.K.H. Brodie (eds.): Controversy in Psychiatry. Philadelphia, W.B. Saunders Co., 183-193.

276. Electroshock therapy: myths and realities. Hosp. Pract. 13:77-82.

277. EEG and psychopharmacology. In Cobb, W.A. and van Duijn, H. (eds.): Contemporary Clinical Neurophysiology Suppl. 34,Electroenceph. Clin. Neurophysiol. 45: 41-56.

278. Book review: Neuropeptide Influences in the Brain and Behavior. Adv. Biochem. Pharmacol. 17: 

L.H. Miller, C.A. Sandman and A.J. Kastin (eds.), NewYork, Raven Press, 298 pp, 1977. Quart. Rev. Biol. 53:195.

279. Book review: Psychopharmacology. A Biochemical and Behavioral Approach. L.S. Seiden and 

L.A. Dykstra (eds.), New York, Van Nostrand Co., 451 pp., 1977. Quart. Rev. Biol. 53: 196.

280. Book review: Psychotherapeutic Drugs. Part 1:Principles. Part 2: Applications. E. Usdin and 

I.S. Forrest (eds.), NewYork, Marcel Dekker, 698+699 pp., 1976. Quart. Rev. Biol. 53: 210-211.

281. Book review: Hemi-Inattention and Hemisphere Specialization. E.A. Weinstein and R.P. Friedland (eds.), New York, Raven Press, 156 pp., 1977. Quart. Rev. Biol. 53: 211.

1979

282a. Convulsive Therapy: Theory and Practice. New York, Raven Press, 308 pp.

282b. Convulsive Therapy: Theory and Practice. Published in Japanese translation, Tokyo, Seiwa Shoten, 394 pp., 1980.

283. Mania and electroseizure therapy (EST). In Shopsin, B. (ed.): Manic Illness. New York, Raven Press, 219-228.

284. A history of convulsive therapy. Psych. Jrl. Univ. Ottawa Fac. Med. 4: 105 - 110.

285. Efficacy of ECT. Lancet 2: 1303 -1304. (letter).

286. EST and other somatic therapies of schizophrenia. In L. Bellak (ed.): Disorders of the Schizophrenic Syndrome. Basic Books, New York, 353-363.

287. CNS effects of the antihistamines, Diphenhydramine and Terfenadine RMI-9918. Pharmakopsych. Neuro-Psychopharmakologie 12: 35, 44 (with P. Irwin).

288a. Phenytoin: EEG effects and plasma levels in volunteers. Therap. Drug Monitoring 1: 93-104 

(with P. Irwin, W. Sannita, Y. Papakostas, M.A. Green).

288b. EEG study of phenytoin in normal volunteers at non-toxic doses. Electroenceph.Clin. Neurophysiol. 49: 83 (abstract).

289a. EEG profile studies of clozapine in volunteers and psychiatric patients.

Pharmakopsych. Neuro-Psychopharmakologie 12: 184-190 (with P. Irwin and P. Weinhold).

289b. EEG effects of clozapine: Association or dissociation of EEG and behavior? Neuro-Psychopharmacology. Oxford, Pergamon, 363-369. (abstract).

290. Anxiety, anxiolytics and the human EEG. In w. Fann, I. Karacen, A. Pokorny, and R.L. Williams, (eds.): Phenomenology and Treatment of Anxiety. New York, Spectrum Publications, 237-250.

291. Neurobiology Group Report, Dahlem Conference. In K.S. Fu and T. Pavlidis (eds.): Biomedical Pattern Recognition and Image Processing. Life Sciences Research Report 15. Verlag Chemie, Basel, 364-394 

(with D.B. Cooper, M. Abeles, G. Bodenstein, et al.).

292. Normal prolactin responses in tardive dyskinesia. Psychopharmacology 66: 247-250 (with G.M. Asnis, E.J. Sachar, G. Langer, F.S. Halpern).

293. Book review: Contemporary Research in Behavioral Pharmacology. D.E. Blackman and D.J. Sanger (eds.), New York, Plenum Press, 506 pp., 1978. Quart. Rev. Biol. 54:118-119.

294. Book review: The Endorphins. Adv. Biochem. Pharmacol. 18. E. Costa and M. Trabucchi (eds.),
New York, Raven Press, 379 pp., 1978. Quart. Rev. Biol. 54: 119.

295. Book review: Rational Anti-epileptic Drugs Therapy. P.J.M. Guelen and E. van der Kleijn. Amsterdam, Elsevier/North Holland. Trends in Neurosciences 2: 492-494.

­

296. Book review: Psychotropic Drugs: A Guide for the Practitioner. H.M. van Praag, New York, Brunner/Maxel, 1978. Comprehens. Psychiat. 20 :494­-495.


1980

297a. A neuroendocrine theory of convulsive therapy. Point of view. Trends in Neurosciences 3: 25-27.

297b. …ibid. Nervenheilkunde 1: 26-29, 1982.

297c. Convulsive therapy and depression: A neurohumoral and neuroendocrine theory. In Saletu, B. (ed.): Neuro-Psychopharmacology. Oxford, Pergamon, 41-44. (abstract).

297d. A theory of convulsive therapy in endogenous depression: Significance of hypothalamic functions. Psychiatry Research 2: 49-61 (with J.O. Ottosson),

298. Convulsive therapy and endogenous depression. Pharmakopsychiat. 13: 49­-54.

299. Neuroendocrinology and ECT: A review of recent developments. Comprehens. Psychiat. 21: 450-459.

300.  ECT, mood and hormones. In D. de Wied and P. A. van Keup (eds.): Hormones and the Brain.
MTP Press, Lancaster, England, 253-262.

301. Convulsive and drug therapies of depression. Ann. Rev. Med. 32: 405-412.

302a. Neuroendocrine measures in psychiatric patients: Course and outcome with ECT. Psychiatry Research 4: 55-64 (with Y. Papakostas, J. Lee, P. Irwin, L. Johnson).

302b. Dexamethasone suppression test and outcome with ECT. In C. Perris, G. Struwe, and B. Jansson (eds.): Biological Psychiatry 1981. 1075-1078, 1981.

303. Random thoughts about ECT. (editorial). Am. J. Psychiat. 138: 484-485.

1981

304. Toward a rational theory of behavior. Career Directions 7: 2-12.

305. An objective classification of psychoactive drugs. Prog. Neuro-Psychopharm. 4: 495-502.

306. EEG and behavioral profile of flutroline (CP-36,584), a novel antipsychotic drug. Psychopharmacology 72: 67-71 (with Peter Irwin).

307. EEG and behavioral effects of pirenzepine in normal volunteers. Scand. Jrl. Gastroenterol. 15 Supplement 66: 39-46 (with Peter Irwin).

308. Classification of psychotropic drugs: Quantitative EEG analysis in man. In van Praag, H.M., Lader, M.H., Rafaelson, O.J. and Sachar, E.J. (eds.): Handbook of Biological Psychiatry. Volume VI. Marcel Dekker, New York, 309-326.

309. The significance of quantitative pharmaco-electroencephalography in establishing dose-time relations and its impact on clinical pharmacology: Critical review and perspectives. Psychopharm. Bull. 17:94. (abstract).

310a. Lateral cerebral differences in psychotropic drug effects. Psychopharm. Bull.17:98. (abstract).
(with Peter Irwin).

310b. Do psychoactive drugs affect the EEG from the cerebral hemispheres differently? In C. Perris, 

D. Kemali and L. Vacca (eds.): Electroneurophysiology and Psychopathology. S. Karger, Basel, Adv. Biol. Psychiat 6: 121-125 (with P. Irwin).

311a. Critical flicker-fusion frequency, EEG, and psychoactive drugs. Psychopharm. Bull. 17: 103. (abstract). (with P. Irwin).

311b. EEG, CFF and behavior. Pharmakopsychiatria 15: 36-38, 1982 (with P. Irwin).

312. A single measure of EEG spectral differences with heuristic value in assessing drug effect. Electroenceph. Clin. Neurophysiol. 51: 32P (abstract).  (with P. Irwin).

313. CNS effects of clonidine in normal volunteers. Psychopharm. Bulletin. 17: 16-17 (with P. Irwin).

314. Pharmaco-EEG and bioequivalence: A practical methodology for psychoactive drugs. Psychopharm. Bulletin 17: 120-121.

315. Pharmacoelectroencephalographic study of brotizolam, a novel hypnotic. Clin. Pharm. Therap. 30: 336-342 (with P. Irwin).

316. EEG and behavioral effects of aspirin in asymptomatic volunteers. In C. Perris, G. Struwe, and 

B. Jansson (eds.): Biological Psychiatry 1981, Elsevier, Amsterdam, 227-229 (with P. Irwin)

317. Clinical trials with des-Tyr-gamma-Endorphin GK-78. In C. Perris, G. Struwe, and B. Jansson (eds.): Biological Psychiatry 1981, Elsevier, Amsterdam, 398-401 (with Y. Papakostas, J. Lee, T. Meehan, 

L. Johnson).

318. Book review: The Psychosurgery Debate. E. S. Valenstein (ed.). W.H. Freeman & Co., San Francisco, 1980. Amer. J. Psychiat. 138: 408-409.

319a. Book review: Divergent Views in Psychiatry. M. Dongier and E. D. Wittkower (eds.). Harper & Row, Hagerstown, MD, 1981. Am. J. Psychiat. 138: 1641.

319b. Divergent views of divergent views: Dr. Fink replies. (letter). Am. J. Psychiat. 139: 1219-1220, 1982.

320. Book review: Neural Peptides and Neuronal Communication. E. Costa and M. Trabucchi (eds.). 

Raven Press, New York, 1980. Quart. Rev. Biol. 56: 98.

321. Book review: Differential Psychopharmacology of Anxiolytics and Sed­atives. J. R. Boissier (ed.). 

S. Karger, Basel, 1979. J. Nerv. Ment. Dis. 169: 469-470.

322. Book review: The Psychodynamic Approach to Drug Therapy. M. Ostow (ed.). Van Nostrand, Reinhold, New York, 1980. Science Books and Films 16: 209.

323. Book review: Law and Ethics in the Practice of Psychiatry. C.K. Hofling (ed.). Brunner/Mazel, 1981. Science Books and Films 17: 64-65.

1982

324. Mianserin. In H. Lehmann (ed.): Non-MAOI and Non-Tricyclic Antidepressants. S. Karger, Basel. Mod. Probl. Pharmacopsychiat. 18: 70-101 (with R. Pinder).

325. Quantitative pharmaco-EEG to establish dose-time relations in clinical pharmacology. 

In W.M. Herrmann (ed.): Electroencephalography in Drug Research. Gustav Fischer, Stuttgart, 17-22.

326a. Guidelines for pharmaco-EEG studies in man. Pharmacopsychiat. 15:107­-108 (with G. Stille, W.M. Herrmann, D. Bente, T.M.Itil, W.P. Koella, S. Kubicki, H. Kunkel, J. Kugler, M. Matejcek. 

and Petsche, H.).

326b. …ibid.,Empfehlungen für pharmakoelektroenzephalographische Untersuchungen am Menschen. EEG-EMG 13: 1-2.

327. Anticholinergic drugs and the EEG. In Committee on Toxicology, National Academy of Sciences. Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents: I: Anticholinesterases and Anticholinergics. National Academy Press, Washington, DC, June 1-8.

328. Neurophysiologic methods to establish antidepressant activity. Neurophysiologische Methoden zum Nachweis antidepressiver Wirkung. Arzneimittelforschung 32: 857-859.

329. CNS effects of acetylsalicylic acid Aspirin (with P. Irwin). Clin. Pharm. Therap. 32: 362-365.

330a. Pharmaco-EEG study of 6-azamianserin ORG-3770: Dissociation of EEG and pharmacologic predictors of antidepressant activity (with P. Irwin). Psychopharmacology 78: 44-48.

330b. …ibid., Psychopharm. Bull. 19: 96, 1983.

331. Blood levels and quantitative EEG response to CNS-active drugs: Retrospective observations. Electroenceph. Clin. Neurophysiol. Suppl. 36: 447-452 (with P. Irwin).

332. Predictors of outcome in convulsive therapy. Psychopharm. Bull. 18: 50-57.

333. Convulsive therapy: A risk-benefit analysis. Psychopharm. Bull. 18: 110­-116.

334. Placebo-controlled studies of ECT. Br. J. Psychiat. 141: 213-214. (letter).

335. Neuroendocrine aspects of convulsive therapy. In R. Abrams and W. Essman (eds.): Electroconvulsive Therapy: Biological Foundations and Clinical Applications. Spectrum Publications, New York, 187-198.

336a. Monitoring the duration of ECT seizures:‘Cuff’ and EEG methods compared (with L. Johnson). 

Arch Gen. Psychiat. 39:1189-1191.

336b. EEG monitoring of ECT preferred to cuff method. Reply. Am. J. Psychiat. 140: 1649, 1983.

336c. ECT Seizure Monitoring. Arch. Gen. Psychiat.: 106-107, 1984 (with L. Johnson). (letter).

337. The enigma of convulsive therapy: An effective, safe and controversial treatment. In J.O. Cavenar and H.K.H. Brodie (eds.): Critical Problems in Psychiatry. J. B. Lippincott, Philadelphia, 203-219.

338. ECT in the elderly. In C. Eisdorfer and W.E. Fann (eds.): Treatment of Psychopathology in the Aging. Springer Publishing Co., New York, Chapter 7, 97-111.

339. ECT in anxiety: An appraisal. Am. J. Psychother. 36: 371-378.

340. The present status of electroconvulsive therapy. Directions in Psychiatry. Hatherleigh Co. Ltd., 

New York, 35:1-8.

341. Book reviews: ECT in Great Britain. J. Pippard and L. Ellam: Electroconvulsive Treatment in Great Britain, 1980. Gaskell, London, 162 pp., 1981; and R. L. Palmer (ed.): Electroconvulsive Therapy: An Appraisal. Oxford, New York 316 pp., 1981. Am. J. Psychiat. 139:958-959.

342. Book review: Drug Development Research. H. Lal and S. Fielding (eds.). A.R. Liss, New York. Quart. Rev. Biol. 57: 234.

1983

343. Guidelines for electroconvulsive therapy in the elderly. In T. Crook and G. D. Cohen (eds.): Physicians’ Guide to the Diagnosis and Treatment of Depression in the Elderly. Mark Powley Associates, New York, VI: 55-60.

344. Missed seizures and the bilateral-unilateral electroconvulsive therapy controversy. Am. J. Psychiat. 140: 198-199. (editorial).

345. Bias against ECT: again. Contemp. Psychol. 28: 246-247. (letter).

346. Antidepressant effects of electroconvulsive therapy. Br. Med. J. 286:1744 ­1745. (letter).

347. Electroshock and Berkeley: II. Biol. Psychiat. 18: 610-613. (editorial).

348. ECT and depression: What have we learned? In F.J Ayd, I.J. Taylor, and B.T. Taylor (eds.):
Affective Disorders Reassessed: 1983. Ayd Medical Communications, Baltimore, pp. 56-72.

349. Pharmacoelectroencephalography. Neuropsychobiol. 9: 45-46. (editorial). (with D. Bente and
H. Kunkel).

350. Book review: The Unfathomed Mind: A Handbook of Unusual Mental Phenomena. W.R. Corliss.
Glen Arm, MD, 754 pp., 1981. Science Books and Films 18: 242.

351. Book review: Neurobiology. G. M. Shepherd. Oxford University Press, NY, 611 pp., 1983. Science Books and Films 19: 83.

352. Book reviews: Advances in Biochemical Pharmacology. Vol. 31. Typical and Atypical Antidepressants: Molecular Mechanisms. Vol. 32: Clinical Practice. E. Costa and G. Racagni (eds.). Raven Press, N.Y. 391 pp. and 400 pp., 1982. Non-Tricyclic and Non-Monoamine Oxidase Inhibitors. H.E. Lehmann (ed.).
S. Karger, Basel, 1982. Quart Rev. Biol. 58: 300-301.

1984

353. Theories of the antidepressant efficacy of convulsive therapy ECT. In R.M. Post and J.C. Ballenger (eds.): Neurobiology of Manic Depressive Illness. Williams & Wilkins, Baltimore, 721-730.

354. Theories of convulsive therapy: A neuroendocrine hypothesis. In B. Lerer, R.Weiner, and R.H. Belmaker (eds.): ECT: Basic Mechanisms. John Libbey &. Co., London, pp. 115-123.

355a. Convulsive therapy: Fifty years of controversy. Clin. Neuropharmacol. 7.Supplement 1: 8-9 (abstract).

355b. Meduna and the origins of convulsive therapy. Am. J. Psychiat. 141: 1034­-1041.

356. Neuroendocrine aspects of the relief of melancholia by induced seizures ECT. In E. Usdin, M. Asberg, L. Bertilsson, and F. Sjoqvist (eds.): Frontiers in Biochemical and Pharmacological Research in Depression. Adv. Biochem. Psychopharm. 39: 345-357.

357. Pharmaco-EEG effects of antihypertensive agents. Clin. Neuropharmacol. 7 Supplement 1: 119 (abstract).

358. Familiarization session and the placebo control in EEG studies of drug effects. Neuropsychobiology. 10: 173-177 (with P. Irwin).

359. ECT: For whom is it justified? J. Clin. Psychopharmacol. 4: 303-304 (editorial).

360. The present status of unilateral ECT: Some recommendations. Jrl. Affective Dis. 7:245-247 (editorial). (with R. Abrams).­

361. Book review: L.B. Kalinowsky, H. Hippius, and H.E. Klein. Biological Treatments in Psychiatry.
Grune & Stratton, New York, 424 pp., 1982. Compr. Psychiatr. 25: 126-127.

362. Book reviews: Vaillant, G. E. The Natural History of Alcoholism. Harvard Univ. Press, Cambridge, MA, 359 pp., 1983; B. Tabakoff, P.B. Sutker, and C.L. Randall (eds.): Medical and Social Aspects of Alcohol Abuse. Plenum Press, New York, 403 pp., 1983; R.G. Smart, F.B. Glaser, Y. Israel, H. Kalant, R.E. Popham, and W. Schmidt (eds.): Research Advances in Alcohol and Drug Problems vol. 7, Plenum Press, New York, 472 pp., 1983. Quart. Rev. Biol. 59: 369-370.

363. Book review: P. Carlton. A Primer of Behavioral Pharmacology. W. H. Freeman & Co., 301 pp., 1983. Quart. Rev. Biol. 59: 511-512. 

1985

364. Pharmaco-electroencephalography: A note on its history. Neuropsychobiology. 1984; 12: 173-178.

365. Convulsive Therapy. Convulsive Ther. 1985; 1: 1-3. (editorial).

366. Reducing memory loss in electroconvulsive therapy. Convulsive Ther. 1985; 1: 77-80. (editorial).

367.  A ‘gratuitous’ conclusion on ECT. Am J Psychiatry 1985; 142: 1129. (letter).

368. Anesthesia in electroconvulsive therapy. Convulsive Ther. 1985; 1: 155-157. (editorial).

369.  Convulsive therapy: Fifty years of progress. Convulsive Ther. 1985; 1: 204­- 216.

370. The ethics of placebo. In L. White, B. Tursky, G.E. Schwartz (eds.): Placebo: Theory, Research and Mechanisms. Guilford Press, New York, 1985; 423-430.

371. Anesthesia in ECT. J Clin Psychopharmacol. 1985; 5: 312. (letter).

372. MAOI, anesthesia, and ECT. J Clin Psychopharmacol 1985; 5: 313. (with K. Freese).

373. National Institutes of Health Consensus Conference on ECT. Convulsive Ther. 1985; 1: 231-233. (editorial).

374. Pharmaco-EEG as a method to assess bioequivalence of CNS active substances in man. Integrative Psychiatry 1985; 3 Supplement: 12S-19S.

375. Summary. Integrative Psychiatry 1985; 3 (Supplement): 92s-93s (with L. Hollister).

376. Book review. E.A. Turner. Surgery of the Mind. Carmen Press, Birmingham UK, 238 pp., 1982.
In Am J Psychiatry 1985; 142: 374-375.

377. Book review. M. Fraser. ECT: A Clinical Guide. John Wiley, New York, 134 pp., 1982. In Convulsive Ther 1985; 1: 66-67.

378. Book review. N.S. Endler. Holiday of Darkness: A Psychologist’s Personal Journey Out of Depression. Wiley-Interscience, New York, 169 pp., 1982. In Convulsive Ther. 1985; 1: 140-142.

379. Book reviews: L. Kalinowsky, H. Hippius, H.E. Klein. Biological Treatments in Psychiatry. Grune & Stratton, New York, 424 pp., 1982; R. Abrams, W.B. Essman (eds.): Electroconvulsive Therapy: Biological Foundations and Clinical Applications. Spectrum Publications, New York, 270 pp., 1982. In Convulsive Ther. 1985; 1: 222-223.

380. Book review: S.E. Luria. A Slot Machine, A Broken Test Tube. Harper & Row, New York, 230 pp., 1984. In Am J Psychiatry 1985; 142: 1210-1211.

381. Book review: G.G. Nahas. Marijuana in Science and Medicine. Raven Press, New York, 312 pp., 1984. In Quart Rev Biol. 1985; 60: 551-552.

382. Book review: R.G. Smart et al.(eds.): Research Advances in Alcohol and Drug Problems. Vol 8. Plenum Press, New York, 333 pp. In Quart Rev Bioi 1985; 60: 552.

1986

383. Neuroendocrine predictors of ECT outcome: DST and prolactin. Annals New York Academy Sci 1986; 462: 30-36.

384. Convulsive therapy today: A decade of increased understanding and acceptance. Psychiatry Letter 1986; 4: 7-12.

385a. Historical Article: Autobiography of L. J. Meduna. Convuls Ther. 1985; 1(1): 43-57.

385b. Autobiography of L.J. Meduna. Ideggyogyaszati szemle 1986; 39: 225­-34. (article in Hungarian).

386.  Electroconvulsive therapy today. Currents 1986; 5: 5-12. (interview).

387. Convulsive therapy and epilepsy research. In M.R. Trimble and E.H. Reynolds (eds.): What is Epilepsy? The Clinical and Scientific Basis of Epilepsy. Churchill Livingstone, Edinburgh, 1986, 217-228.

388. Serial dexamethasone suppression tests in ECT. Clin Neuropharm 1986; 9: Suppl. 4: 444-446
(with K. Gujavarty K, L. Greenberg). (abstract).

389. Multi-lead EEG dynamic mapping during ECT. Clin Neuropharm 1986; 9: Suppl. 4: 536-537
(with M. Fink, L. Greenberg, K. Gujavarty). (abstract).

390. Convulsive therapy: How it evolved. Psychopharm Bull 1986; 22: 357-459.

391. A new evaluation of convulsive therapy: The Ontario report. Convulsive Ther 1986; 2: 73-76 (editorial).

392. Training in ECT. Convulsive Ther 1986; 2: 227-230. (editorial).

393. Book review: J. Winson. Brain and Psyche: The Biology of the Unconscious. New York, Doubleday, 1985, 300 pp. In Science Books and Films 1986; 21: 157.

394. Book review: D.C. Horwell (ed.): Drugs in the Central Nervous System Disorders. New York, Marcel Dekker Inc. 1985, 354 pp. In Quart Rev Biol 1986; 61: 146.

1987

395. Serial dexamethasone suppression tests and clinical outcome in ECT. Convulsive Ther 1987; 3: 111-120 (with L. Greenberg, K. Gujavarty).

396. Electroconvulsive therapy and neuroleptic medication in the treatment of therapy resistant positive-symptom psychosis. Convulsive Ther 1987; 3: 185­-195 (with K. Gujavarty, L. Greenberg).

397. Isoflurane anesthesia therapy: A replacement for ECT in depressive disorders? Convulsive Ther 1987; 3: 269-277 (with L.B. Greenberg, J. Gage, S. Vikun).

398. Update on ECT. Psychiatric Annals 1987; 17: 47-53 (interview).

399. Convulsive therapy in affective disorders: A decade of understanding and acceptance. In H. Meltzer (ed.): Psychopharmacology: A Third Generation of Progress. Raven Press, New York, 1987, Chap 108: 1071-1076.

400. ECT: A last resort treatment for resistant depression? In J. Zohar, R. Belmaker (eds.): Treating Resistant Depression. PMA Publishing Co, New York, Chap 9: 163-173.

401. Convulsive therapy. In G Adelman (ed.): Encyclopedia of Neuroscience. Birkhuser, Boston, 1987, 277-278.

402. Neuroendocrine aspects of convulsive therapy: Review of recent developments. In C.B. Nemeroff,
P.T Loosen (eds.): Handbook of Clinical Psychoneuroendocrinology. Guilford Press, New York, 1987, Chapter 11: 255­-265.

403. New technology in convulsive therapy: A challenge in training. Am J Psychiatry 1987; 144: 1195-1196 (editorial).

404. Neuropsychiatry and behavioral neurology. Convulsive Ther 1987; 3: 91-92 (editorial).

405. Is ECT usage decreasing? Convulsive Ther 1987; 3: 171-173. (editorial).

406. Maintenance ECT and affective disorders. Convulsive Ther 1987; 3: 249-250 (editorial).

407. Contraindications to electroconvulsive therapy. Anesth Analg 1987; 66: 918 (letter).

408. A case of resistant schizophrenia. Br J Psychiatry 1987; 150: 562-563 (letter).

409.  Book review: A.V. Valdman (ed.): Drug Dependence and Emotional Behavior: Neurophysiological and Neurochemical Approaches. Plenum Publ Co., New York, 1986. In Quart Rev Biol 1987; 62: 120-121.

410. Book review: W. Kalow, H.W. Goedde, D.P. Agarwal (eds.): Ethnic Differences in Reaction to Drugs and Xenobiotics. AR Liss, New York, 583 pp., 1986. In Quart Rev Biol 1987; 62: 124.

411. Book review: M.H. Van Woert, E. Chung (eds.): Cooperative Approaches to Research and Development of Orphan Drugs. AR Liss, New York, 204 pp., 1985. In Quart Rev Biol 1987; 62: 124-125.

412. Book review: E.S. Valenstein. Great and Desperate Cures. Basic Books, New York, 338 pp., 1986.
In Convulsive Ther 1987; 3: 79-81.

413. Book review: M. Brause, A.M. Zimmerman (eds.): Genetic and Perinatal Effects of Abused Substances. Academic Press, New York, 211pp., 1987. In  Quart Rev Biol 1987; 62: 469.

1988

414. Prospective electroconvulsive therapy in delusional depressed patient with a frontal meningioma.
Br J Psychiatry 1988; 153: 105-107 (with L.B. Greenberg, R. Mofson).

415. Convulsive therapy for affective disorders. In A. Georgeotas and R. Cancro (eds.): Depression and Mania. Elsevier, North Holland and New York, 1988; 29: 452-460.

416. Convulsive therapy: A manual of practice. Review of Psychiatry VII. 1988;21: 482-497. APA Press, Washington DC.

417. The present status of electroconvulsive therapy: An update. F. Flach (ed.): Directions in Psychiatry 1988; 1-8. Hatherleigh Co., New York.

418. Forward. Electroconvulsive Therapy, Richard Abrams, 1st ed., Oxford University Press, New York, 1988; vii-x.

419. Forward. Electroconvulsive Therapy: The Myths and the Realities. N.S. Endler, E. Persad, Hans Huber, Toronto; 1988; ix-xi.

420. Fifty years of electro-convulsive therapy. Convulsive Ther 1988; 4: 2-4 (editorial).

421. ECT for Parkinson disease? Convulsive Ther 1988; 4: 189-191 (editorial).

422. How does ECT work? Psychopharmacol Bull 1988; 24: 385-386 (with W. Potter).

423. Neuroendocrine hypothesis of antidepressant action of ECT. Psychopharmacol Bull 1988; 24: 400-402.

424. Use of ECT in the United States. Am J Psychiatry 1988; 145: l33-134. (letter).

425. ECT instrumentation. Biol Psychiatry 1988; 24: 360-361. (letter).

426. The diagnosis and treatment of depression in the old. JAMA 1988; 260: 1405. (letter).

427. ECT: The continuing controversy. Consensus in Psychiatry 1988; 1: 1.

428. Brain imaging and pharmaco-EEG. Consensus in Psychiatry 1988; 1: 1-2.

429. Book review: Kurt Eissler: Freud as an Expert Witness. IUP Press, Madison CT, 1986. In Convulsive Ther 1988; 4: 250-251.

430. Book reviews: M.A. Taylor, F.S. Sierles, R. Abrams. General Hospital Psychiatry. Free Press, New York, 1985; A. Stoudemire, B.S. Fogel (eds.): Principles of Medical Psychiatry. Grune & Stratton, Orlando FL, 1987; A.J. Frances, R.H. Hales (eds.): Review of Psychiatry VII, American Psychiatric Press, Washington DC, 1988. In Convulsive Ther 1988; 4: 175-177.

431. Book review: I. Rosenfield. The Invention of Memory: A New View of the Brain. Basic Books, 

New York, 1987. In Science Books &Films 1988; 24: 77-78.

432. Book reviews: B. Aperia. A Psychoendocrinological Study of Electroconvulsive Therapy in Major Depressive Disorder. Thesis. Department of Psychiatry, Karolinska Institute, St Gyran’s Hospital, Stockholm, Sweden, 1985. P. Silfverskiyld. Depression and Mania: Clinical and Neurophysiological Aspects and Effects of ECT. Thesis. Department of Psychiatry, University of Lund, Lund, Sweden, 1987. In Convulsive Ther 1988; 4: 177-179.

433. Book review: Current Approaches: ECT. J. Malkien, S. Brandon. Duphar Laboratories, UK, 1988. 

In Convulsive Ther 1988; 4: 335-336.

434. Book review: R.E. Hales, S.C. Yudofsky (eds.): Textbook of Neuropsychiatry. APA Press, Washington DC, 1987. In Neuropsychiatry, Neuropsychol Behav Neurology 1987; 1: 153-155.

435. Book review: P.H. Wender. The Hyperactive Child, Adolescent and Adult: Attention Deficit Disorder Through the Lifespan. Oxford University Press, New York, 162 pp., 1987. In Science Books &Films, 1988; 23: 244.

436. Videotape Review: Healthcare Information Network, Princeton NJ. Electroconvulsive Therapy: A New Age, A New Understanding. Series: Mind and Body. Distributed by MECTA Corporation, Portland OR, 1987. In Convulsive Ther 1988; 4: 180.

1989

437. Convulsive therapy: A reappraisal. In J.G. Howells (ed.): Modern perspectives in the Psychiatry of Affective Disorders. Brunner/Mazel Inc., New York, 1989; 22: 393-410.

438. Electroconvulsive therapy: The forgotten option in the treatment of therapy­ resistant depression.
In I. Extein (ed.): Treatment of Tricyclic Resistant Depression. APA Press, Washington DC, 1989, 135-150.

439. A comparison of etomidate and methohexital anesthesia for electroconvulsive therapy. Annals Clin Psychiatry 1989; 1: 39-42 (with L.B. Greenberg, R. Boccio).

440. A neuroendocrine view of ECT. Convulsive Ther 1989; 5: 296-304 (with C.B. Nemeroff).

441. Convulsive therapy and kindling. In M. Trimble and T. Bolwig (eds.): The Clinical Relevance of Kindling. John Wiley & Sons, Chichester. 1989; 13: 195­- 208.

442.  Electroconvulsive therapy: A review. Organorama 1989; 26: 24-25.

443. Update on “Shock” therapy. Health &Medical Horizons. Macmillan Co., New York, 1989; 197-198 (commentary).

444. Recommendations for EEG and evoked-potential mapping. Neuropsychobiology 1989; 22: 170-176. International Pharmaco-EEG Group; (with W. Herrmann et al.).

445. Reversible and irreversible dementia. Convulsive Ther 1989; 5: 123-125 (editorial).

446. ECT in Parkinson disease. The Psychiatric Times 1989; 63: 6-7. (commentary).

447. Maintenance ECT is a continuing saga. The Psychiatric Times 1989; 64: 13-­14. (commentary).

448. Reversible dementia and ECT. The Psychiatric Times 1989; 65: 23-24. (commentary).

449. Primo Levi need not have died. The New York Times. January 5, 1989. A20. (letter).

450. The efficacy of electroconvulsive therapy in therapy-resistant psychotic patients. J Clin. Psychopharmacol 1989;9: 231-232. (letter).

451.  Max Hamilton. Biol Psychiatry 1989; 26: 218-219. (homage).

452. Maintenance ECT. In response. Jefferson Jrl Psychiatry 1989; 7: 71-72 (letter).

453. Videotape review: J. David. Four Lives: A Portrait of Manic Depression. Fanlight Productions, 1988. Hosp & Commun Psychiatry 1989; 40: 347-348.

454. Book review: Lader M., Lang R., Wilson G.D. Patterns of Improvement in Depressed In-Patients. Oxford University Press, Oxford UK, 1987, 118 pp. In J Nerv Ment Dis 1989; 177: 498-499.

1990

455. How does convulsive therapy work? Neuropsychopharmacology 1990; 3: 73­-82.

456. Response to commentaries on “How does convulsive therapy work?” Neuropsychopharmacology 1990; 3: 97-100. 

457. Electroconvulsive therapy and cyclophosphamide in combination for severe neuropsychiatric lupus with catatonia. Am J Medicine 1990; 88: 443-444 (with G.L. Fricchione, L.D. Kaufman, B.L. Gruber).

458. Rat brain concentration of fluphenazine during a course of electroconvulsive shock. Convulsive Ther 1990; 6: 273-9 (with I. Zervas, L.B.Greenberg, R.F. Suckow, T. Cooper, L. Jandorf).

459. Electroconvulsive therapy in the elderly. Psychiatric Annals 1990; 20: 99-101. (with L.B. Greenberg). (review).

460. Electroconvulsive therapy. Current Opinion in Psychiatry 1990; 3: 58-61. (review).

461. Electroconvulsive therapy of anxiety disorders. In R. Noyes, M. Roth, G.D. Burrows (eds.): Handbook of Anxiety IV: The Treatment of Anxiety. Elsevier Science Publishers BV, Amsterdam, Chap 25: 511-518, 1990.

462. A trial of ECT is essential before a diagnosis of refractory depression is made. In J.D. Amsterdam (ed.): Refractory Depression. Adv Neuropsychiatry Psychopharmacology 1990; 2: 87-92. Raven Press, New York.

463. Is catatonia a primary indication for ECT? Convulsive Ther 1990; 6: 1-4. (editorial).

464. The 1990 APA task force report: A quiet revolution. Convulsive Ther 1990;6: 75-78. (editorial).

465.  ECT in modern literature. Convulsive Ther. 1990; 6: 191-193. (editorial).

466. Electrode placement: A clinician’s guide. Convulsive Ther. 1990; 6: 263-265. (editorial).

467. Clozapine andelectroconvulsive therapy. Arch Gen Psychiatry 1990; 47: 290­-291. (letter).

468. Continuation ECT today. Harvard Medical School Mental Health Letter. (forum). 1990; 6: 8.

469. Guidelines for the long-term use of convulsive therapy. JAMA 1990; 264: 1174. Questions and answers.

470. Book review: L.G. Kiloh, J.S. Smith, G.F. Johnson. Physical Treatments in Psychiatry. Blackwell Scientific, Melbourne, 1988. In Am J Psychiatry 1990;147: 1239-1240.

471. …ibid.,In Convulsive Ther. 1990; 6: 60-62. 


472. Book review: M.R. Trimble, E.H. Reynolds (eds.): Epilepsy, Behaviour and Cognitive Function.
John Wiley & Sons, Chichester UK, 1988. In Am J Psychiatry 1990; 147: 665-666.


473. Energy parameters of ECT devices need reassessment. Psychiatric Times 1990;7: 23, 26. (commentary).

474. Catatonia and ECT. Psychiatric Times 1990; 7: 32-33. (commentary).

1991

475. Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta­endorphin and somatostatin. Br J Psychiatry 1991; 158: 59-63 with C.B. Nemeroff, G. Bissette G, H. Akil).

476. Catatonia: A separate category for DSM-IV? Integrative Psychiatry 1991; 7: 2­-

10 (with M.A. Taylor).

477. Impact of the anti-psychiatry movement on the revival of ECT in the U.S. Psychiatric Clinics N.A. 1991; 14: 793-801.

478. Electroconvulsive therapy, 1989-1990. Current Opinion Psychiatry 1991; 4: 73-77 (with I. Zervas).

479. The revival of ECT in America. Bolletino di Psichiatria Biologica. 1991:6: 25-29.

480. What is an adequate treatment in convulsive therapy? Acta Psychiatr Scand 1991; 84: 424-427.

481. Electroconvulsive therapy. Review of APA Task Force report. Wn Jrl Med 1991; 155, 515. (review).

482. Present use of ECT. Integrative Psychiatry 1991; 7: 69-70. (letter).

483. Pharmacotherapy and ECT. Convulsive Ther 1991; 7: 77-80. (editorial).

484. A scientific society for ECT. Convulsive Ther 1991; 7: 155-156. (editorial).

485. ECT for refractory Parkinson’s Disease. Convulsive Ther 1991; 7: 222-223 (with I. Zervas). (letter).

486. A historical review of electroconvulsive therapy. Jefferson Jrl Psychiatry 1991;9: 97-99. (letter).

487. Steroid induced catatonia. Br J Psychiatry 1991; 159: 445. (letter).

488.  ECT in long-term follow up of BPD. Biol Psychiatry 1991; 30: 1172. (letter).

1992

489. Soziale und politische Aspekte der Elektrokonvulsionstherapie in den USA: Lektionen fur die deutsche Psychiatrie. Social and political aspects of ECT in the U.S.: Lessons for German psychiatry). Biologische Psychiatrie. Springer Verlag, Heidelberg, 1992, 88-90.

490. The use of ECT in geriatric patients. In G.S. Alexopoulos (ed.): Clinics Geriatric Medicine 1992; 8: 349-354, W.B. Saunders: Philadelphia (with L.B. Greenberg).

491. Electroconvulsive therapy. In E.S. Paykel (ed.): Handbook of Affective Disorders. 2nd ed. Churchill-Livingstone, London, 1992; 22: 359-368. (review).

492. Induced seizures ECT and memory. In D Barcia Salorio (ed.): Trastornos de la Memoria. Editorial MCR, Madrid. 1992; 5.1: 383-396.

493. Pharmaco-Electroencephalography: A science ignored. Pharmacopsychiatry 1992; 24: 183-184. (editorial).

494. Qualification for ECT. Convulsive Ther 1992; 8: 1-4 (with R. Abrams). (editorial).

495. ECT and public mental health services. Convulsive Ther 1992; 8: 87-91. (editorial).

496. Catatonia and DSM-IV. Convulsive Ther 1992; 8: 159-162. (editorial).

497. Book review: Electroconvulsive therapy. Psychiatric Clinics N.A. 1992; 14: 693,­1020. 

In Convulsive Ther 1992; 8:54-55.

498. Book review: ECT awaits its Lavoisier. R. Abrams. Electroconvulsive Therapy, 2nd ed. Oxford University Press, New York, 340 pp., 1992. In Convulsive Ther 1992; 8:213-216.

499. Book review: B.N. Gangadhar (ed.). Proceedings of the National Workshop on ECT. NIMHANS, Bangalore, India, 264 pp., 1992. J Krzyzowski. Leczenie Elektrowstrzasami. Z.D. Poligraficzny, Warsaw, Poland, 215 pp., 1991. In Convulsive Ther 1992; 8: 216-217.

500. Failure to use ECT in a case of catatonia. Am J Psychiatry 1992; 149: 145. (letter).

501. The treatment of catatonia: Benzodiazepines or ECT? P.J. Rosebush, A.M. Hildebrand, M.F. Mazurek (letter). Dr. Fink replies. Am J Psychiatry 1992;149: 1279-1280. (letter).

502. ECT response in catatonia. Am J Psychiatry 1992; 149: 581-582 (with A. Francis). (letter).

503. Why not ECT for catatonia? Biol Psychiatry 1992; 31: 536-537. (letter).

504. ECT and delirium in Parkinson’s Disease. Jrl Neuropsychiatry &Clin Neuroscience 1992; 4: 231
(with I. Zervas). (letter).

505. Follow-up: Letter on review of APA Task Force report by Peter Breggin. Readings: A Journal of Reviews and Commentary. American Orthopsychiatry Association). 1992; 7:22-23 (with L. Eisenberg). (letter).

506. Role of Dopamine in mood disorders. Comprehens Psychiatry 1992; 33: 417-417 (with L. Fochtmann). (letter).

507. ECT and delirium in Parkinson's Disease. Am J Psychiatry 1992; 149: 1758 (with I. Zervas). (letter).

508. Missed neuroleptic malignant syndrome. BMJ 1992; 304: 1246. (letter).

509. Catatonia: incidence and treatment in a university hospital. Convulsive Ther 1992; 8: 60-61
(with I. Zervas, J. Pataki J). (abstract).

1993

510. Blood pressure, memory, and electroconvulsive therapy. Convulsive Ther 1993; 9: 14-22
(with I. Zervas, A. Calev, L. Jandorf).

511a. Caffeine pre-treatment enhances clinical efficacy and reduces cognitive effects of ECT. Convulsive Ther 1993;  9:95-100 (with A. Calev, G. Petrides,  A. Francis, L. Fochtmann). 

511b. Effect of ECT with caffeine pre-treatment on efficacy for depression and memory deficits. Biol Psychiatry 1993; 33:84A (with A. Calev).

512. Who should get ECT? In C.E. Coffey (ed.): The Clinical Science of Electroconvulsive Therapy. 1993; 1: 3-16. APA Press, Washington, DC.

513. Catatonia: A treatable disorder, occasionally recognized. Directions in Psychiatry. 1993; 13(3): 1-8
(with G. Bush, A. Francis).

514. Die Geschichte der EKT in den USA in den letzten Jahrzehnten. (Recent history of electroconvulsive therapy in the U.S.) Nervenarzt. 1993; 64: 689-95.

515. Subjective symptoms in depression and during the course of electroconvulsive therapy. Neuropsychiatry, Neuropsychol Behav Neurol. 1993; 6: 187-92 (with N. Tubi, A. Calev, D. Niga1, B. Shapira, H.L. Pass, 

L. Jandorf, B. Lerer).

516. Post-ECT delirium. Convulsive Ther 1993; 9: 326-330. (review).

517. Reversible dementia and affective disorder: The Rip van Winkle Syndrome. Convulsive Ther 1993; 9: 209-16 (with L. Bright-Long). (case report).

518. Combining drugs and electroconvulsive therapy: Safe and/or effective? J. Clin. Psychopharmacology 1993; 13 2): 85-86. (commentary).

519.  Prolonged seizures. Convulsive Ther 1993; 9: 87-89. (commentary).

520. ECT in children and adolescents. Convulsive Ther 1993; 9: 15S-7. (commentary).

521a. The next challenge: The mode of action of ECT. Convulsive Ther 1993; 9: 192-7. (annotation).

521b. The mode of action of ECT. Psychopharmacol. Bull. 1994; 30: 309-12, 1994.

522. ECT and drugs: Concurrent administration. Convulsive Ther 1993; 9: 237-40. (with C.H. Kellner). (commentary)

523. Commentary on J.B. Welch: Topographic brain mapping: Applications and pitfalls. Integrative Psychiatry 1993; 9: 67-8.

524. EEG and behavior: Association or dissociation in man? Integrative Psychiatry 1993; 9: 108-123. (hypothesis).

525. Catatonia and psychotic delusional depression, distinct syndromes in DSM­-IV. Am. J. Psychiatry 1993; 150: 1130-1. (letter).

526. Using MEDLINE to solve clinical problems. JAMA 1993; 270: 2053 (letter).

527. Book review: “Round up a new set of suspects...” Review of M.K. O’Connor, T.A. Rummans (eds): Updating ECT. Psychiatric Annals, 1993; 23:1­-47. In Convulsive Ther 1993; 9: 141-2.

528. Book review: Psychiatry: The next phase. Review of M. Taylor: The Neuropsychiatric Guide to Modern Everyday Psychiatry. The Free Press, New York, 530 pp., 1993. In Convulsive Ther. 1993; 9: 143-5.

529a. Question the Experts: Blood levels of nortriptyline. J Clin Psychopharmacology 1993; 13: 296.

529b. Reply to “Question the Experts.” J Clin. Psychopharmacology 1993; 13: 359.

530. Book review: Psychiatry’s frog or prince? Electroconvulsive Therapy. Richard Abrams, Oxford University Press, 1992. In BJP Review of Books 6:18-19, July, 1993.

531. Book review: Electroconvulsive Therapy. Richard Abrams, Oxford University Press, 1992, 2nd ed.
In Am. J. Psychiatry 1993; 150:1747-8.

532. Book review: Neuropsychological Perspectives on Emotion. F.N. Watts. Hillsdale, NJ: Lawrence Erlbaum. In Science Books &Films 1993; 29:261.

533. Book review: Motor Disorders in Psychiatry. D. Rogers, Wiley & Sons, Chichester UK, 1992. 

In Neuropsychiatry, Neuropsychol Behav Neurol 1993;6: 267-8.

534a. Catatonia: A rating scale and prospective study utilizing lorazepam and ECT. Amer Col Neuropsychopharmacology Abstracts, pg 88, December 1993 (with G. Bush, A. Francis, G. Petrides, 

F. Dowling).

534b. What is catatonia? The Harvard Mental Health Letter 1995; 11: 8 (with G. Bush, G. Petrides). (commentary).

1994

535a. Continuation ECT for relapse prevention in depression. Convulsive Ther 1994;10: 77 (with G. Petrides, D. Dhossche). (abstract).

535b. A prospective study of continuation ECT. Biol. Psychiatry 1994; 35: 652-3 (with G. Petrides ,
D. Dhossche, A. Francis). (abstract).

535c. Continuation ECT: Relapse prevention in affective disorders. Convulsive Ther 1994; 10: 189-94
(with G. Petrides G., D. Dhossche, A. Francis).

536. Indications for the use of ECT. Psychopharmacol. Bull. 1994; 30: 269-80.

537a. Combining electroconvulsive therapy and drugs: A review of safety and efficacy. CNS Drugs 1994; 1: 370-376. (review).

537b. ECT and psychoactive drugs combined. ASCP Progress Notes Newsletter 1994; (52): 3. (review).

538. Optimizing ECT. L’Encephale 1994; 20: 297-302. (review).

539a. ECT in adolescents. The Harvard Mental Health Letter 1994; 10: 8. (commentary).

539b. ECT in adolescents. Psychiatric Times 1994; 12: 18-19,1995. (commentary). 

540a. Catatonia in DSM-IV. Biological Psychiatry 1994; 36: 431-3. (commentary).

540b. DSM-IV and catatonia. Psychiatric Times 1994; 11: 35. (commentary).

541. Public perceptions of ECT. Jefferson Jrl. Psychiatry 1994; 12: 83-86. (letter).

542. Administrative problems limiting electroconvulsive therapy. Br. J.Psychiatry 1994; 164: 850-1. (letter).

543. Diazepam or lorazepam for prolonged seizures? Convulsive Ther 1994; 10: 236. (letter).

544. Convalescence and ECT. Convulsive Ther. 1994; 10: 301-3. (letter).

545. Book review: The Clinical Science of Electroconvulsive Therapy. C.E. Coffey (ed.), American Psychiatric Press, Washington DC, 259 pp., 1993. In The Psychiatric Times, Feb. 1994, pg. 25.

546. Book review: Drugs and Disease. J. L. Harris. Twenty-First Century Books, New York, 1993.
In Science Books 1994; 30: 82.

547. Book review: Cannabis, Politically Incorrect. Marihuana, The Forbidden Medicine. L. Grinspoon,
J.B.  Bakalar. Yale University Press, New Haven, CT, 1993. In Am. J.Psychiatry 1994; 151: 1091.

548. The half-age stimulation strategy for bilateral ECT. Biol. Psychiatry 1994; 35: 653 (with G. Petrides). (abstract).

549. Alternative stimulation strategies for bilateral ECT. Convulsive Ther 1994;10: 77 (with G. Petrides). (abstract).

1995

550. Convulsive therapy in delusional disorders. Psychiatric Clinics North America 1995; 18 (2): 393-406. (review).

551.  ECT and non-memory cognition: A review. Br. J. Clin Psychology 1995; 34: 505-15 (with A. Calev, E.A. Gaudino, N.K. Squires, I.M. Zervas).

552. Recognizing NMS as a type of catatonia. Neuropsychiatry Neuropsychol Behav Neurol. 1995; 8: 75-6. (commentary).

553.  Treat NMS as catatonia. Psychiatric Times 1995; 12 (3): 34. (commentary).

554.  ECT in mania: A rediscovered use. Psychiatric Times 1995; 12 (6): 16.

555.  ECT and schizophrenia. Psychiatric Times 1995; 12 (10): 30.

556. Milton Greenblatt: a remembrance. Convulsive Ther 1995; 11: 151-3 (with F. Frankel).

557.  Convalescence and ECT: Comment on Letter by Dr. Brackin. Convulsive Ther 1995; 11: 220-21. (letter).

558. ECT and young minds. Lancet 1995; 345: 519. (letter).

559. NMS and catatonia: Reply to Raja and Miti. Neuropsychiatry Neuropsychol Behav Neurol 1995;8: 230-1. (letter).

560. “An ethical dilemma ....” Psychiatric Bulletin 1995; 19: 650-1 (with D.F. Klein). (letter).

561. ECT and pre-pubertal children. J Am Acad Child Adolesc Psychiatry 1995; 34: 1256-7
(with G.A. Carlson). (letter).

562. Book review: F.E. Bloom, O.J. Kupfer (eds.): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995, 2002 pp. In Neuropsychiatry, Neuropsychol. &Behav Neurol. (84): 303-4.

563. Book review: Asaad, Ghazi: Understanding mental disorders due to medical conditions or substance abuse: What every therapist should know. Brunner Maazel, NY, 1995. In Science Books &Films 31 (5): 134-5. (book review).

564. Book review: J. Morrison: DSM-IV Made Easy: The Clinician’s Guide to Diagnosis. Guilford Press, NY, 1995. In Science Books &Films 31 (8): 233.

1996

565. Atrial fibrillation, anticoagulation, and electroconvulsive therapy. Convulsive Ther. 1996; 12: 91-98 (with G. Petrides).

566. Ambulatory electroconvulsive therapy. Task force report of the association for convulsive therapy. Convulsive Ther. 1996; 12: 42-55 (with R. Abrams, S. Bailine, R. Jaffe).

567. Convulsive therapy for schizophrenia? Schizophrenia Bull. 1996; 221: 27­-39 (with H.A. Sackeim).

568. Catatonia: I: rating scale and standardized examination (with G. Bush, G. Petrides, F. Dowling,
A. Francis). Acta psychiatr. Scand 1996; 93 (2): 129­-36.

569. Catatonia: II. Treatment with lorazepam and electroconvulsive therapy (with G. Bush, G. Petrides,
F. Dowling, A. Francis). Acta Psychiatr. Scand 1996;93 (2):137-43.

570. Catatonia. In T.A. Widiger, A.J. Frances, H.A. Pincus et al. (eds.): DSM-JV Sourcebook, 1996; vol 2:181-192.

571.  The “half-age” stimulation strategy for ECT dosing. Convulsive Ther 1996;12: 138-146
(with G. Petrides).

572. Toxic serotonin syndrome or neuroleptic malignant syndrome? Pharmacopsychiatry 1996; 29: 159-161. (case report).

573. A second quiet revolution: Ambulatory ECT. Convulsive Ther 1996; 12: 1-2 (with C.H. Kellner). (editorial).

574.  Seizure adequacy: Does EEG hold the key? Convulsive Ther. 1996; 12: 203­-206 (with C.H. Kellner). (editorial).

575. Neuroleptic malignant syndrome and catatonia: One entity or two? Biol Psychiatry 1996; 39: 1-4. (editorial).

576. Ambulatory ECT and managed care. The Psychiatric Times 1996; 13: 42.

577. Response to “Neuroleptic malignant-like syndrome due to cyclobenzaprine?” J Clin Psychopharmacol. 1996; 16: 97-9. (letter).

578. “Abnormal EEG effects of Clozapine.” J Neuropsych Clin Neuroscience 1996; 8: 114-115. (letter).

579. Algorithm accuracy. Comment on the International Psychopharmacology Algorithm Project. Psychiatric Times 1996; 13(8): 5. (letter).

580. Treating the syndrome before the complications. Am J Psychiatry 1996;153: 1371 (with A. Francis). (letter).

581. Choosing a dosing strategy for electrical stimulation in ECT. J Clin Psychiatry 1996; 57: 487.
(with G. Petrides). (letter).

582. ‘Catatonic schizophrenia’ is not ‘schizophrenia.’ Schizophrenia Res 1996;18: 118. (abstract).

583. Book review: C. P. Freeman (ed.): The ECT Handbook. Royal College of Psychiatrists, London, 153 pp., 1995. In Convulsive Ther 1996; 12: 127-130.

584. Book review: Bergsholm P.: Electroconvulsive Therapy: Issues related to narcosis, physiology, radiological anatomy, electrode placement, and endocrinology. Forde/Bergen, University of Bergen, 1995. In Convulsive Ther 1996; 12: 131-132.

1997

585. Catatonia. In M. Trimble, J. Cummings (eds.): Contemporary Behavioural Neurology. 1997; Chapter 16; pages 289-309. Butterworth/Heinemann, Oxford, UK.

586a. Prejudice against ECT: Competition with psychological philosophies as a contribution to its stigma. Convulsive Ther 1997; 13: 253-265.

586b. Response to Zigmond M. Lebensohn. Convulsive Ther 1997; 13: 268.

586c. Electroshock and psychoanalysis: schism in American psychiatry. Convulsive Ther 1997; 13: 51-52.

587. Recognition and treatment of the catatonic syndrome. Jrl Intensive Care Med. 1997; 12: 135-147
(with G. Fricchione, G. Bush G, M. Fozdar, A. Francis). (review).

588. Neuroleptic malignant syndrome: Identification and treatment. Essential Psychopharmacology. 1997; 2: 209-16. (review and commentary).

589. Energy dosing in ECT: Threshold stimulation or formula? Convulsive Ther. 1997; 13: 4-6. (debate with Richard Weiner).

590. Clinical common sense versus theoretical correctness. Reply to Harold A. Sackeim. Convulsive Ther. 1997; 13: 41-43 (with G. Petrides).

591. The decision to use ECT: For Whom? When? In A.J. Rush (ed.): Mood Disorders: Systematic Medication Management. Modern Probl. Pharmacopsychiatry. 1997; 25: 203-214. Karger, Basel, Switzerland.

592. Electroconvulsive therapy in affective disorders: Efficacy and mode of action. In A. Honig, H.M. van Praag (eds.): Depression: Neurobiological, Psychopathological and Therapeutic Advances. 1997; Chapter 23, pages 397­-412. John Wiley & Sons, Ltd. Sussex, England.

593. What is the role of ECT in the treatment of mania? The Harvard Mental Health Letter 1997; 18: 8.

594. Cognitive screening instruments in neuropsychiatry: A report of the committee on research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci. 1997; 9:189-97 (with P.F. Malloy, J.L. Cummings, C.E. Coffey, J. Duffy, E.C. Lauterbach, M. Lovel, D. Royall, S. Salloway).

595. Lethal catatonia, neuroleptic malignant syndrome, and catatonia: A spectrum of disorders. Reply. J Clin Psychopharmacol. 1997; 17: 237. (letter).

596. The importance of a differentiated psychopathology of catatonia. Acta Psychiatr. Scand. 1997; 95: 358-9 (with G. Petrides, G. Bush, A. Francis).  (letter).

597. ECT Update. Psychiatric Times. 1997; 14: 39-41. (review and lesson).

598. Catatonia and NMS: Recognition and treatment. The Psychiatric Times. 1997;14: 42-49. (review and lesson).

599. A.E. Bennett and curare. Convulsive Ther 1997; 13: 92. (commentary).

600. Book review: Squire L. A History of Neuroscience in Autobiography. Washington DC, Society for Neuroscience. vol 1, 1996. In Science Books & Films 1997; 33: 137.

601. Book review: New histories of psychiatry: Somatic and dynamic views contrasted. Shorter E. A History of Psychiatry. From the Era of the Asylum to the Age of Prozac. John Wiley & Sons, N.Y. 1997; Stone MH. Healing the Mind. A History of Psychiatry from Antiquity to the Present. W.W. Norton & Co., N.Y. 1997. 

In Convulsive Ther 1997; 13: 280-1.

1998

602. Electroconvulsive therapy and managed care. Am Jrl Managed Care. 1998; 4: 107-112 (with S. Bailine).

603. ECT and managed care. Journal Watch: Psychiatry. 1998; 4: 76 (73).

604. ECT in older patients: Benefits and risks. Psychiatric Times 1998; 15(2): 68­-71. (lesson).

605. ECT certification. J ECT 1998; 14: 1-4 (with C.H. Kellner). (editorial).

606. ECT and clozapine in schizophrenia. J ECT 1998; 14: 223-6. (editorial).

607. ECT in mania: An ignored and effective treatment option. Jrl Bipolar Disorders 1998; 2: 19-21. (review).

608. Electroconvulsive therapy. In C.E. Coffey and R. Brumback (eds.): Textbook of Pediatric Neuropsychiatry, 1998; Chapter 54: 1389-1408. American Psychiatric Press, Washington, DC
(with C.E. Coffey).

609. EEG monitoring in ECT: A guide to treatment efficacy. Psychiatric Times 1998; 15 (5): 70-2
(with R. Abrams).

610. Misguided consent for ECT. Austral NZ Jrl Psychiatry. 1998; 31: 209. (letter).

611. Theophylline and ECT. J ECT 1998; 14: 286-9 (with H.A. Sackeim). (letter).

612. Delirium following cessation of alcohol consumption. Am J Psychiatry 1998; 155: 1638.

613. Pharmaco-electroencephalography: A debate in psychopharmacology. In T. Ban, D. Healy, E. Shorter (eds.): The Rise of Psychopharmacology and the Story of the CINP, 1998; 151-6. Animula Publishing House, Budapest.

614. The case for formal certification in ECT. J ECT 1998; 14: 132. (abstract).

615. To titrate or not to titrate: A debate with a twist. J ECT 1998; 14: 133-4. (abstract).

616. Concurrent use of ECT and atypical antipsychotic medications. J ECT 1998;14: 139-40
(with G. Petrides, A. Abaza, A. Francis). (abstract).

617. Book review: Principles of Neuropsychopharmacology. R.S. Feldman, J.S. Meyer, L.F. Quenzer. Sinauer: Sunderland, MA, 1997. In Quart Rev Biol 1998; 73: 122.

618.  Video Review: Brainstorm: The Hidden Epidemic of Depression. Filmakers Library, New York, 1998; 53 min. video. In Science Books &Films 1998;34: 150.

1999

619a. ELECTROSHOCK: Restoring the Mind. Oxford University Press, New York, 157 pp. Re-issued in paperback as Electroshock: Healing Mental Illness, 2002.

619b.  Eletrochoque. Restaurando a Mente. Portugese translation by Dra. Andrea Favano. Sao Paulo Brazil: Editora Roca Ltda, 2003.

620.www.electroshock.org.(website, July 1999).

621a. Electroconvulsive therapy and mental retardation. J ECT 1999; 15: 140-9 (with M. Thuppal).

621b. Electroconvulsive therapy and mental retardation. J ECT 1998; 14: 142 (with M. Thuppal). (abstract).

622. Delirious mania. Bipolar Disorders 1999; 1: 54-60.

623. ECT in delirious states. J ECT 1999; 15: 175-77. (editorial).

624. Convulsive therapy. In G. Adelman, B.H. Smith (eds.): Elsevier’s Encyclopedia of Neuroscience. Elsevier Science. B.V., New York and Amsterdam, 466-468, 1999.

625. Convulsive Therapy. In H. Freeman (ed.): A Century of Psychiatry, Mosby-Wolfe, London, 1999; I:
96-99; II: 229-32.

626. Ladislas J. Meduna. Images in psychiatry. Am J Psychiatry 1999; 156: 1807.

627. Intractable seizures, status epilepticus, and ECT. J ECT 1999; 15: 282-4 (with C. Kellner,
H.A. Sackeim). (letter).

628. Pediatric ECT. Psychiatric Times 1999; 169: 63-5 (with C. Foley).

629. Neuroleptic malignant syndrome: Recognition and treatment. Psychiatric Times 1999; 16 (8): 6. (commentary).

630. Book review: J.L. Beyer, Weiner R.D., Glenn M.D.: Electroconvulsive Therapy: A Programmed Text. American Psychiatric Press, Inc., Washington DC, 1998, Am J. Psychiatry 1999; 156: 333.

2000

631. Electroshock revisited. Amer Scientist 2000; 88 (2): 162-167.

632. Catatonia. In C. Andrade (ed.): Advances in Psychiatry. New Delhi, Oxford University Press. Chapter 2, pp. 26-44, 2000 (with G. Petrides).

633. A clinician-researcher and ECDEU: 1959-1980. In T. Ban, D. Healy, E. Shorter (eds.): The Triumph of Psychopharmacology and the Story of the CINP. Budapest, Animula, 2000, 82-96, 2000.

634. Can delirium relieve psychosis? Comprehens Psychiatry 2000; 41: 450-453 (with C. Malur, A. Francis).

635. ECT has proved effective in treating depression. Nature 2000; 405: 826. (letter).

636. The interaction of delirium and seizures. In P.T. Trzepacz (ed.) Seminars in Clinical Neuropsychiatry 2000; 52: 31-35.

637. Educational resources for electro-convulsive therapy. Arch Indian Psychiatry 2000; 6: 6-9.

638a. ECT in the management of delirium, NMS, and catatonia. Essential Psychopharmacology 2000; 3: 1-16.

638b. ECT in the management of delirium, NMS, and catatonia. Directions in Psychiatry 2000; 220: 367-376. (lesson).

639. Herman C.B. Denber. Neuropsychopharmacology 2000; 23:474-475. (obituary).

640. Undiagnosed Stupor: A treatable syndrome of catatonia? ASCP Progress Notes 2000; 10: 1,4,7.

641. Fixed high dose right unilateral ECT. (commentary). Evidence-Based Mental Health 2000; 3: 114-115.

642. Controversies in the diagnosis and treatment of manic-depressive illness. World Jrl Biological Psychiatry 2000; 1: 219. (letter).

643. NMS best treated as catatonia. Psychiatric Times 2000; 17 (11): 28-29. (commentary).

644. Book review: The Science of Happiness: Unlocking the Mysteries of Mood. Stephen Braun. NY, Wiley, 2000. In Science Books &Films, 2000:36 (5): 212.

645. A neuroendocrine view of convulsive therapy. Neuropsychopharmacology 2000; 23: S91. (abstract).

2001


646. Convulsive therapy after 65 years. J Affective Dis. 2001; 63: 1-15.

647. ECT remission rates in psychotic versus non-psychotic depressed patients: A report from CORE.
J ECT 2001;17: 244-253 (with G. Petrides, M.M. Husain, R. Knapp, A.J. Rush, M. Mueller, T.A. Rummans, K.M. O’Connor, K.G. Rasmussen, H.J. Bernstein, M. Biggs, S.H. Bailine, C.H. Kellner).

648. The influence of age on the response ofpatients with major depression to electroconvulsive therapy. Am J Geriatr Psychiatry 2001; 9: 382-390 (with K.M. O’Connor, R. Knapp, M.M. Husain, T.A. Rummans, G. Petrides, G. Smith, M. Mueller, K. Snyder, H. Bernstein, A.J. Rush, C. Kellner).

649. ECT has much to offer our patients: It should not be ignored. World Jrl Biological Psychiatry 2001; 2: 1-8.

650. Electroconvulsive therapy in medication-resistant depression. In Jay Amsterdam, Mady Hornig-Rohan, and Andrew Nierenberg (eds.): Treatment ­resistant mood disorders. 2001; 11: 223-238. Cambridge University Press, Cambridge UK.

651. Convulsive therapy in the 21st Century. In M.G. Gelder, J.J. Lopez-Ibor and N.C. Andreasen (eds.): New Oxford Textbook of Psychiatry, Oxford University Press, London. Chap 6.2.9.1; pp. 1342-1352.

652. The many varieties of catatonia. European Arch Psychiatry Clin Neurosci 2001;251: Suppl 1: 8-13 (with M.A. Taylor).

653. Catatonia: Syndrome or schizophrenia subtype? Recognition andtreatment. J Neural Transmission 2001; 108: 637-644.

654. The broad clinical activity of ECT should not be ignored. J ECT 2001; 17: 233235. (editorial).

655. New research improves ECT outcomes. Psychiatric Times 2001; 18: 21. (review).

656. Electrode placement and electroconvulsive therapy: A search for the chimera. Arch Gen Psychiatry. 2001; 58: 607-608. (with S. Bailine, G. Petrides). (letter).

657. Modal ECT is effective: Response to Letter by Sackeim et al. J ECT 2001; 17: 222-225. (letter).

658. Treating neuroleptic malignant syndrome as catatonia. J Clin Psychopharmacol. 2001; 21: 120-121. (letter).

659. Treating manic stupor. Indian J Psychiatry 2001; 433: 286-287. (letter).

660 Treating bipolar affective disorder. BMJ 2001;322: 365. (letter).

661. Book review: A Century of Psychiatry. Hugh Freeman. London, Mosby-Wolfe Medical Communications. In Neuropsychiatry, Neuropsychology Behavioral Neurology 2001; 14: 77.

2002


662. The efficacy of ECT and “Treatment Resistance.” J ECT 2002; 18: 1-2.

663. Move On! Commentary on R. Abrams: stimulus titration and EC T dosing. J ECT 2002; 18: 11-12.

664. Catatonia and ECT. Reconsidering Meduna’s hypothesis of a biological antagonism between dementia praecox and epilepsy. World Jrl Biol Psychiatry 2002; 3: 105-108.

665. The 21st century clinical evaluation of psychoactive drugs. In T. Ban, D. Healy, E. Shorter (eds.):
From Psychopharmacology to Neuropsychopharmacology in the 1980s and the Story of CINP as told in Autobiography. Budapest: Animula Publishing, 2002; 21-26.

666. ECT: an effective, but ignored, treatment of psychosis. In B. Green (ed.): Focus on Antipsychotics. London: Librapharm/Petroc Press, 2002, 3: 10-17.

667. Equivalency of rTMS and ECT unproven. Biol Psychiatry 2002; 52: 1032-1033 (with C.H. Kellner,
M. Husain, G. Petrides, T. Rummans). (letter).

668. Electrotherapeutics. J ECT 2002; 18: 114-115.

669. Catatonia and NMS. (Grand Rounds Response) Psychiatric Bull. 2002; 26: 393. (with M.A. Taylor). (letter).

670. ECT in neurological disorders. Psychiatric Times 2002; 19 (9): 28-29.

671. Catatonia in adolescents and children. Psychiatric Times 2002; 19 (9): 28-29.

672. Book review: American Psychiatric Association. The Practice of Electroconvulsive
Therapy: Recommendations for Treatment, Training and Privileging.
2nd ed. Psychiatric Services.
2002; 53: 1040-1041.

673. Book review: Rage Against Electroshock. Kneeland TW, Warren CAB. Pushbutton Psychiatry. Westport CT: Praeger, 2002. J ECT 2002; 18: 112­-113.

674. Book review. Electricity in Medicine: Ugo Cerletti’s Contribution. Electric Bodies: Episodes in the History of Medical Electricity. Paola Bertucci, Giuliano Pancaldi (eds.). Bologna, Italy: Universita di Bologna, 2001. J ECT 2002; 18:165-166.

2003

675a. Catatonia. A Clinician’s Guide to Diagnosis and Treatment. Cambridge UK: Cambridge University Press (with M.A. Taylor).

675b. Catatonia. Guía clinica para el diagnóstico y el tratamiento. Translated into Spanish by
Beatriz M. Ruiz and Miguel B. Arroyo. Barcelona: Masson, 2005.

675c. …ibid., Translated into Japanese by Kazumasa Suzuki. Tokyo: Seiwa Shoten, 2007.

676. Catatonia in psychiatric classification: A home of its own. Am J Psychiatry 2003; 160: 1233-1241
(with M.A. Taylor).

677. A Beautiful Mindand insulin coma: social constraints on psychiatric diagnosis and treatment. Harvard Review of Psychiatry 2003; 11: 284-290.

678. A Gilles de la Tourette form of catatonia: Response to ECT. J ECT 2003;19(2): 115-117.
(with H. Trivedi, A. Mendelowitz).

679. ECT Update: Recognizing and treating psychotic depression. J Clin Psychiatry 2003; 64: 232-234.

680. Therapy-Resistant Depression: When to consider ECT. Algorithm seeks respect for neglected therapy. Current Psychiatry 2003; 2: 49-54.

681. Commentary on “Successful use of ECT as the sole modality of treatment in a case of motility psychosis”: The classification of catatonia. J ECT 191: 48­- 49, March 2003 (with M.A. Taylor).

682. Electroshock 2003. Masterminds Indian Psychiatric Society (Jan) 2003, 3-4.

683. Letter from India: Conflicts in the use of ECT. Psychiatric Times 2003 (Mar); 20: 10.

684. Book review. A classic text updated. Abrams R: Electroconvulsive Therapy, New York: Oxford University Press. J ECT 2003; 19:123-124. ibid.Psychiatric Times 2003 (Jun); 20: 25.

685. Book review. D. Healy. The Creation of Psychopharmacology. Cambridge MA: Harvard University Press, 2002. Psychiatric Times 2003; 220: 29.

686. Book review. G. Parker, D. Straton, K. Wilhelm, P. Mitchell; M-P. Austin, K. Eyers, D. Hadzi-Pavlovic. Dealing with Depression: A Commonsense Guide to Mood Disorders. New South Wales: Crows Nest, 2002. Am J Psychiatry 2003; 160:1365-1366.

687. Book review: K. Hugdahl, R.J. Davidson. The Asymmetrical Brain. Cambridge MA: MIT Press, 2003. Science Books &Films 2003;9: 160.

2004

688a. Ethics of Electroconvulsive Therapy. New York: Brunner-Routledge (with J.O. Ottosson).

688b. …ibid., Translated into Japanese by Mitsuru Nakamura. Tokyo: Seiwa Shoten, 2006.

689. Pharmaco-Electroencephalography: A Selective History of the Study of Brain Responses to Psychoactive Drugs. In History of CINP, vol IV. Edited by T. Ban, E. Shorter, D. Healy. pp. 661-672.

690. Speed of Response and Remission in Major Depressive Disorder with Acute ECT: A Consortium for Research in ECT (CORE) Report (with M.M. Husain, A.J. Rush, R. Knapp, G. Petrides, T. Rummans,
M.M. Biggs, K.M. O’Connor, K. Rasmussen, M. Litle, W. Zhao, H.J. Bernstein, G. Smith, M. Mueller, S.M. McClintock, S.H. Bailine, C.H. Kellner). J Clin Psychiatry 2004; 65: 485-491.


691. Efficacy of ECT in catatonia. In S.Caroff, S.Mann, A. Francis, G Fricchione (eds.): Catatonia. From Psychopathology to Neurobiology. Washington DC: American Psychiatric Press. 13: 151-160
(with G. Petrides, C. Malur).

692. Induced seizures as psychiatric therapy: Ladislas Meduna’s contributions in modern neuroscience. J ECT 2004;20: 133-136. (commentary).

693. Response to T.E. Schlaepfer: Learning from the history of neuroscience: Dogma and patient interests. J ECT 2004; 20: 138.

 694. Melancholy or Malarky? In Spitzer R.L., First M.B., Gibbon M., Williams J.B.W. (eds.): Treatment companion to the DSM-IV-TR casebook. Washington DC: American Psychiatric Publishing, 2004; 112-119.

695. Response to critique: classification of catatonia. Am J Psychiatry 2004;161: 1136 (with M.A. Taylor). (letter).

696. Response. Catatonia in psychiatric classification. Am J Psychiatry 2004;161: 2328.

697. Non-convulsive status epilepticus and electroconvulsive therapy. J ECT 2004;20: 131-2. (letter).

698. Treat TSS and NMS as malignant catatonia. BMJ (rapid responses) 2004; 329: 1333-1335.


699. Convulsive therapy electroshock (ECT). In G. Adelman, B.H.Smith (eds.): Encyclopedia of Neuroscience, 3rded. Amsterdam: Elsevier B.V., 2004.

700. Insulin coma therapy (ICT). Encyclopedia of Neuroscience. In G. Adelman, B.H. Smith (eds.): Encyclopedia of Neuroscience, 3rdedition. Amsterdam: Elsevier B.V., 2004.

701. About Meduna’s pioneer activity. Neuropsychopharmacol Hung 2004; 6: 39. (letter).

702. ECT: Serendipity or logical outcome? Psychiatric Times 2004; 211: 21-22.

703. A new appreciation of ECT. Psychiatric Times 2004; 214: 32-35.

704. ECT at 70: What have we learned? Psychiatric Times 2004; 21(8): 13-14.

705. Book review. The Mount Everest Challenge. Lisanby S.H. (ed.): Brain Stimulation in Psychiatry. Washington DC: American Psychiatric Publishing Inc. Am J Psychiatry. 2004 (161): 2149-2150.

706. Book review. Schroeder B.E.: Ecstasy. Philadelphia: Chelsea House, 2003. Science Books and Films 2004 (May-June); 127.

2005


707. Catatonia. Guia clinica para el diagnóstico y el tratamiento. (Spanish translation). Barcelona: Masson Elsevier.

708. Psychobiology of Electroshock. In J. Licinio (ed.): Biology of Depression. Weinheim, Germany: Wiley-VCH, 2004. Chap 7: 211-221.

709. Relief of expressed suicidal intent by ECT: A Consortium for Research in ECT Study. Am J Psychiatry 2005;162: 977-982 (with C.H. Kellner, R. Knapp, G. Petrides, M.M. Husain, T. Rummans, M. Mueller,
H. Bernstein, K. Rasmussen, K. O’Connor, G. Smith, A.J. Rush, M. Biggs, S. McClintock, S.H. Bailine,
C. Malur).

710. Should the dexamethasone suppression test be resurrected? Acta Psychiatrica Scandinavica 2005; 112: 245-9. (commentary). 

711. Is the practice of ECT ethical? World Jrl Biological Psychiatry 2005;6 (Supplement 2): 38-43.

712. The “treatment resistant” label in bipolar disorder is a misnomer. Psychiatric Annals 2005; 35: 965-8. (review).

713. Predicting the response to ECT. J ECT 2005;21(3): 137-8. (editorial). (with V. McCall).

714. William Karliner: practitioner, experimentalist, and teacher. Obituary. J ECT 2005;21: 201-2.

715. Suicide risk reduced. Psychiatric Times 2005; 222: 94-95.

716. The bean-counters view of ECT. Psychiatric Times 22; 10: 54.

717. Continuation ECT Today: What we know and what we need to know. Psychiatric Times 2005; 2214: 76-77.

718. Use of pharmacologic coma for adult status epilepticus. Epilepsy &Behavior. 2005; 6: 292 (letter).
(with D. Anschel).

719. Cheap shot at ECT. Lancet 2005; 365: 937 (with C. Kellner, V. McCall). (letter).

720. Book review. Kelleher, C.A.: Brain Trust. New York: Paraview Pocket Books, 2004. Science Books and Films 2005; 41:105.

721. Book reviews. Scull A. Madhouse: A Tragic Tale of Megalomania and Modern Medicine. New Haven: Yale University Press, 2005; J. El-Hai. The Lobotomist: A Maverick Medical Genius and his Tragic Quest to Rid the World of Mental Illness. New York: Wiley, 2005. J ECT 2005; 21: 191-3.

722. Book review. A. Scull: Madhouse: A Tragic Tale of Megalomania and Modern Medicine. New Haven: Yale University Press, 2005. Science Books and Films 2005; 41: 251.

2006

723. Melancholia: The Diagnosis, Pathophysiology, and Treatment of Depressive Disorders. Cambridge UK: Cambridge University Press, 2006 (with M.A. Taylor).

724. Catatonia in autistic spectrum disorders: A medical treatment algorithm. In D. Dhosshe, L. Wing,
M. Ohta, K-J Neumarker (eds.): Catatonia in Autism Spectrum Disorders. Amsterdam: Elsevier/Academic Press. Int Rev Neurobiology 2006; 72:233-244 (with M.A. Taylor, N. Ghaziuddin).

725. Patterns of Psychotropic Medication Use Among Severely Depressed Patients Referred for Electroconvulsive Therapy: Data from the Consortium for Research on ECT. J ECT 2006;22: 116-123
(with K.G. Rasmussen, M. Mueller, C.H. Kellner, R.G. Knapp, G. Petrides, T.A. Rummans, M.M. Husain,
K. O’Connor, J.L. Black, S. Sampson).

726. Continuation ECT versus pharmacotherapy for relapse prevention in major depression: a multi-site study from CORE. Archives General Psychiatry. 2006; 63: 1337-44 (with C.H. Kellner, R.G. Knapp, G. Petrides, T.A. Rummans, M.M. Husain, K. Rasmussen, M. Mueller, H.J. Bernstein, K. O’Connor, G. Smith, M. Biggs, S.H. Bailine, C. Malur, E. Yim E, S. Sampson, M Fink).

727. The case against evidence-based principles in psychiatry. Medical Hypotheses 2006; 67: 401-410.
(with R.L. Levine).

728. Catatonia: Subtype or syndrome in DSM? Am J Psychiatry 2006; 163 (11): 1875-6, (with M.A. Taylor). (commentary).

729. Challenges to British ECT clinical practice. J ECT 2006;22: 30­-32. (commentary).

730. ECT in therapy-resistant mania: Does it have a place? Bipolar Disorders 2006; 8: 307-9. (commentary).

731. The DST riddle. Psychiatric Times 2006; 23 (2): 25-26.

732. Should the diagnosis of melancholia be revived? Psychiatric Times 2006; 23 (6): 78-80.

733. The Camelford hysteria: A lesson for ECT? Psychiatric Times 2006; 23 (11): 69­-72.

734. Interseizure EEG slowing after ECT is not NCSE. Pharmacopsychiatry 2006; 39: 119. (letter).

735. Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. Prog NeuroPsychopharmacol Biol Psychiatry 2006;30:1182-1183. (with M.A. Taylor). (letter).

736. Book review: G.S. Ungvari. Catatonia: An anthology of classical contributions.  Hong Kong: Scientific Communications Int. Ltd. 2006. J ECT 2006; 22: 277-8.

737. AV Review: Healthy Brains. Chip Taylor Communications. Science Books & Films 2006; 42: 138. (review).

2007

738. Resurrecting melancholia. Acta psychiatrica scandinavica 2007; Supplement 433: 14-20
(with M.A. Taylor).

739. Melancholia: Restoration in psychiatric classification recommended. Acta Psychiatr Scand. 2007; 115: 89-92 (with T.G. Bolwig, G. Parker, E. Shorter). (conference summary).

740. DSM melancholic features are unreliable predictors of ECT response: A CORE publication. J ECT. 2007; 23: 139-146 (with A.J. Rush,  R. Knapp, K. Rasmussen, M. Mueller, T. Rummans, K. O’Connor,
M. Husain, M. Biggs, S. Bailine, C.H. Kellner, and CORE group.)

741. Antidepressant Treatment Failure Does Not Predict Lower Remission Rates with ECT for Major Depressive Disorder. A Report from the Consortium for Research in ECT. J Clin Psychiatry 2007; 68: 1701-1706 (with K.G. Rasmussen, M. Mueller, R.G. Knapp, M.M. Husain, T.A. Rummans, S.M. Sampson, M.K. O’Connor, G. Petrides, C.H. Kellner).

742. Electroconvulsive therapy: Evidence and challenges. JAMA 2007; 298: 330­-332 (with M.A. Taylor).

743. Complaints of the loss of personal memories after electroconvulsive therapy: Evidence of a somatoform disorder? Psychosomatics 2007; 48: 290-293.

744. Data management and design issues in an unmasked randomized trial of electroconvulsive therapy for relapse prevention of severe depression. J ECT 2007;23: 244-250 (with K.G. Rasmussen, R.G. Knapp,
M.M. Biggs, G.E. Smith, T.A. Rummans, G. Petrides, M.M. Husain, M.K. O’Connor, C.H. Kellner).

745. Belling the cat: ECT practice standards in the United States. J ECT 2007;23: 3-5 (with C.H. Kellner). (commentary).

746. What we learn about continuation treatments from the collaborative ECT studies.  J ECT 2007;23: 215-218 (commentary).

747. Ambulatory electroconvulsive therapy. J ECT 2007;23: 130. (history).

748. Antidepressant medications and other treatments of depressive disorders: A CINP Task Force report based on a review of evidence. International Journal of Neuropsychopharmacology 2007; 10: S1-S207. (with N. Sartorius, T.C. Baghai, D.S. Baldwin, B. Barrett, D. Brand, W. Fleischhacker, G. Goodwin, H. Grunze, M. Knapp, B.E. Leonard, J. Lieberman, Y. Nakane, R.M. Pinder, A.F. Schatzberg, J. Svestka, P. Baumann, K. Ghalib, J.C. Markowitz, F. Padberg, T. Furukawa, K.N. Fountoulakis, P. Jensen, S. Kanba, A. Riecher-Rossler).

749. Improving electroconvulsive therapy practice. Psychiatric Times 2007; 24 (4): 10-11.

750. Electroshock works. Why? Psychiatric Times 2007; 24 (6): 59-60.

751. Major studies on ECT for depression: What have we learned? Psychiatric Times 2007; 24 (12): 26-28.

752. Catatonia or no catatonia: Still beyond lorazepam/amobarbital. Letter and Reply. Am J Psychiatry 2007; 164: 525 (with M.A. Taylor).

753. The renaissance of ECT. Forward for Electroconvulsietherapie: Aanbevelingen voor de praktijk.
P. Sienaert, J. De Fruyt, M. Dierick (eds.). Ghent: Academic Press, 2007: xv-xviii.

754. …ibid., Book review: Dukakis K, Tye L. SHOCK: The Healing Power of Electroconvulsive Therapy. New York: Penguin Group, 2006. J ECT 2007; 23: 131-133. Commentary: Ambulatory electroconvulsive therapy (p.130).

2008

755. Restoring melancholia in the classification of mood disorders. Jrl Affective Disorders 2008; 105: 1-14 (with M.A. Taylor).

756. The medical evidence-based model to identify psychiatric syndromes: Return to a classical paradigm. Acta Psychiatr Scand 2008; 87: 81-84 (with M.A. Taylor).

757. Karoly Schaffer and his school: The birth of biological psychiatry in Hungary, 1890-1940. Eur Psychiatry 2008; 23(6):449-456. (with B. Baran, I. Bitter, G. Gazdag, E. Shorter).

758. Change in seizure threshold during ECT: A CORE study. J ECT 2008; 24: 114­-116 (with G. Petrides, C.H. Kellner, M. Mueller, R. Knapp, M.M. Husain, K. Rasmussen, T.A. Rummans, K. O’Connor).

759. Outcome of ECT by race in the CORE multi-site study. J ECT 2008; 24: 117­-121 (with M. Williams, T. Rummans, S. Sampson, R. Knapp, M. Mueller, M. Husain, K. Rasmussen, K. O’Connor, G. Smith, G. Petrides, C.H. Kellner).

760a. The efficacy of acute ECT in atypical depression. J Clin Psychiatry 2008; 69: 406-411 (with
M.M. Husain, S.M. McClintock, A.J. Rush, R.G. Knapp, T.A. Rummans, K. Rasmussen, C. Claassen,
G. Petrides, M.M. Biggs, M. Mueller, S. Sampson, S.H. Bailine, C.H. Kellner).

760b. ECT not proven for atypical depression. Response to Letter C.M. Swartz. JClin Psychiatry 2008; 69: 1662-3. (with M.M. Husain, S.M. McClintock, A.J. Rush, R.G. Knapp, T.A. Rummans, K. Rasmussen, C. Claassen, G. Petrides, M.M. Biggs, M. Mueller, S. Sampson, S.H. Bailine, C.H. Kellner, S.H. Lisanby).

761. Conceptual issues in DSM-V development (commentary). Am J Psychiatry 2008; 165: 799.
(with M.A. Taylor).

762. Continuation treatments for melancholic depression. Commentary to M. Webber: electroconvulsive therapy, BMJ 2008; 337: 2998 (rapid response).

763. Catatonia in autism is treatable. Psychiatric Times 2008; 25: 17, 20.

764. Why evidence-based medicine cannot be applied to psychiatry. Psychiatric Times 2008; 25: 10-12.

2009

765. Electroconvulsive Therapy: A Guide for Professionals &Their Patients. New York: Oxford University Press, 2009.

766. Serendipity and science: A double anniversary of a treatment and a journal.  J ECT 2009; 25: 1-2.

767. Laszlo Meduna’s pilot studies with camphor induction of seizures: The first 11 patients. J ECT 2009; 25: 3-11 (with G. Gazdag, I. Bitter, G.S. Ungvari, B. Baran).

768. Electrotherapy of melancholia: The pioneering contributions of Benjamin Franklin and Giovanni Aldini. J ECT 2009;25:15-18 (with T. Bolwig).

769. Induced therapy in man. In Encyclopedia of Neuroscience. 2009: 5: 117-123. Edited by Larry Squire, Floyd Bloom, Fred Gage, Nick Spitzer. Oxford: Academic Press.

770. Electroconvulsive Therapy. In New Oxford Textbook of Psychiatry. Edited by M.G. Gelder, J.J. Lopez-Ibor, and N.C. Andreasen. New York: Oxford University Press, 2009, vol II;6.2.10.1: 1251-1259.

771. Catatonia: A syndrome appears, disappears, and is rediscovered. Can J Psychiatry 2009; 54: 23-31.

772. Catatonia: Forgotten but not gone. Arch Gen Psychiatry 2009; 66: 1173-77 (with M.A. Taylor).

773. Catatonia in 100 words. Br J Psychiatry 2009; 194: 325 (with M.A. Taylor).

774. Melancholia in 100 words. Br J Psychiatry 2009; 194: 463 (with M.A. Taylor).

775. The electroshock riddle: effective but rejected. Br J Psychiatry 2009; 195: 390.

776. Biological markers for melancholic depression are effective. Comment on the WFSBP Task Force Report. World Journal of Biological Psychiatry 2009 (103):252-3 (with M.A. Taylor).

777. Seizure threshold in a large sample: Implications for stimulus dosing strategies in bitemporal ECT.
A report from CORE (with G. Petrides, R.J. Braga, M. Mueller, R. Knapp, T. Rummans, M. Husain,
K. Rasmuussen, S. Bailine, C. Malur, K. O’Connor, C.H. Kellner). J ECT 2009; 25: 232-237.

778. Electroconvulsive therapy in the treatment of intractable status epilepticus. Epilepsy & Behavior 2009; 16:189-90. (letter). (with C.H. Kellner).
http://dx.doi.org/10.1016/j.yebeh.2009.06.022

779. DSM-V: Applying the medical model. Psychiatric Times. 2009, June 9: 26 (6): http://www.psychiatrictimes.com/display/article/10168/1420772.

2010

780. Endocrine Psychiatry: Solving the Riddle of Melancholia (with E.Shorter). Oxford University Press.

781. Remembering: the forgotten neuroscience of pharmaco-EEG. Acta Psychiatr Scand 2010; 121: 161-73.

782. Catatonia is not schizophrenia: Kraepelin’s error and the need to recognize catatonia as an independent syndrome in medical nomenclature. Schizophrenia Bulletin 2009; doi: 10.1093/schbul/sbp059; 2010; 36: 314-20. (with E. Shorter, M.A. Taylor).

783. The failure of the schizophrenia concept and the argument for its replacement by hebephrenia: applying the medical model for disease recognition (with M.A. Taylor, E. Shorter, N.A. Vaidya). Acta Psychiatr Scand 2010; 122: 173-183.

784. Phenomenology is not enough. J. McCarthy letter (response). Acta Psychiatr Scand. 2011; 123: 82-83. (with M.A. Taylor, E. Shorter, N.A. Vaidya).

785. The intimate relationship between catatonia and convulsive therapy. J ECT 2010;26: 243-245. (commentary).

786. Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. A. Francis ,
F. Appiani, A. Bertelsen, T.G. Bolwig, P. Braunig, S.N. Caroff, B.T. Carroll, A.E. Cavanna, D. Cohen, Cottencin O, M.J. Cuesta, J. Daniels, D. Dhossche, G.L. Fricchione, G. Gazdag, N. Ghaziuddin, D. Healy, D.F. Klein, S. Krüger, J.W.Y. Lee, S.C. Mann, M. Mazurek, W.V. McCall, W.W. McDaniel, G. Northoff,
V. Peralta, Petrides G, P. Rosebush, T.A. Rummans, E. Shorter, K. Suzuki, P. Thomas, G. Vaiva,
L. Wachtel). J ECT 2010; 26: 246-248. (letter).

787. Whither melancholia? The case for its classification as a distinct mood disorder (with G. Parker,
E. Shorter, M.A. Taylor, H. Akiskal, G. Berrios, T. Bolwig, W.A. Brown, B. Carroll, D. Healy, D.F. Klein,
A. Koukopolous, R. Michels, J. Paris, R.T. Rubin, R. Spitzer, C. Swartz). Am J Psychiatry 2010; 167: 745-47. (letter).

788. Laszlo Meduna’s immigration to the United States in 1939: Correspondence with Victor Gonda (G. Gazdag, M. Fink, G. Ungvari, E. Shorter). J ECT 2010;26: 79-81.

789. The human side of Laszlo Meduna. J ECT 26: 77-78. (commentary).

790. ECT is equally effective in unipolar and bipolar depression (with S. Bailine, R. Knapp, G. Petrides,
M. Husain, K. Rasmussen, S. Sampson, M. Mueller, S. McClintock, K.G. Tobias, C.H. Kellner). Acta Psychiatr Scand 2010; 121: 431-436.

791. Bifrontal, bitemporal, and right unilateral electrode placement in ECT: A randomized trial (with
C.H. Kellner, R. Knapp, M. Husain, K. Rasmussen, S. Sampson, M. Cullum, S. McClintock, K. Tobias,
C. Martino, M. Mueller, S. Bailine, G. Petrides). Br. J. Psychiatry 2010; 196: 226-234.

792. A randomized controlled trial comparing the memory effects of continuation ECT versus continuation pharmacotherapy: Results from the CORE study (with G.E. Smith, K.G. Rasmussen, M. Cullum,
M.D. Felmlee, G. Petrides, T.A. Rummans, M. Husain, M. Mueller, H. Bernstein, R. Knapp, M.K. O’Connor,
S. Sampson, S.H. Bailine, C.H. Kellner). J Clin Psychiatry 2010; 71: 185-193.

793. The end of the asylum era in Central-Eastern Europe. History of Psychiatry 2010; 21: 501-504.
(with G. Gazdag, B. Baran, Z. Rihmer).

794. ECT (Electroconvulsive Therapy) as first line treatment for psychotic depression. Letter reply to
B.S. Meyers, A.J. Flynt, A.J. Rothschild et al.:The Study of Pharmacotherapy of Psychotic Depression STOP-PD. Arch Gen Psychiatry 2009; 66:838-47. (with C.H. Kellner, K. Tobias, G. Petrides). Arch Gen Psychiatry, 9 Feb 2010. (letter).

795. F.D. Zepf et al.:A 16-year-old boy with severe gamma-butyrolactone (GBL) withdrawal delirium. Pharmacopsychiatry 2010; 43: 157-8. (letter).

796. The perplexing history of electroconvulsive therapy in three books. Psychiatric Times 2010; (Oct) 27: 31 (with C.H. Kellner). (book review).

797. Book Review. Hysteria: The Biography.  Andrew Scull. New York: Oxford University Press, 2009.  SB&F April 2010.

798. Obituary: Sidney Merlis, 1925-2010. Neuropsychopharmacology 2010:35: 2648.

2011

799. Catatonia from its Creation to DSM5: Considerations for ICD. Indian Jrl  Psychiatry. 2011; 53: 214-217.

800. Melancholia is a distinct identifiable mood disorder that warrants a separate category in DSM5. In: C.R. Soldatos and D.G. Dikeos (Ed): Psychiatry and the Neurosciences: International Perspectives. Bologna Italy: Editografica, 2011: 5-13.

801. ECT resurrected: Its successes and promises after 75 years. Can J Psychiatry  2011; 56:3-4 (Commentary).

802. Presidential Perspective: Defining clinical diagnoses by the medical model. In:  Cottler L (Ed): Mental Health in Public Health: The Next 100 Years, NY: Oxford University Press, 2011: 278-281.

803. Anti-NMDA receptor encephalitis vs. pediatric catatonia. [Comment on Case  Report "Anti NMDA receptor encephalitis" Am J Psychiatry 2011;168: 245-51]. Am J Psychiatry 2011; 168: 749. [Dhossche D, Fink M, Shorter E, Wachtel LE] (Letter)

804. Transcranial magnetic stimulation is not a replacement for electroconvulsive  therapy in depressive mood disorders.  J ECT 2011; 27: 3-4. (Commentary)

805. Stimulus dosing in electroconvulsive therapy. J ECT 2011; 27:268. [Petrides G, Braga RJ, Fink M,

Mueller M, Knapp RG, Husain M, Rummans T, Bailine SH, O'Connor K, Malur C, Kellner CH.]. (Letter)

806. ECT for melancholia. New York City Voices 2011; 18: 16. (Letter)

807. A response to Not “Au Revoir” but "Merci Beaucoup. J ECT 2011; 27:339.  [Bailine S, Petrides G, Kellner C, Fink M, Bolwig T, Freeman C, Greenberg  R, Kramer B, Fox H, Francis A, O'Connor K, Ray L, Satin A, Guerra F, Hermann C, Kayne E, Sevi S, Braga R.] (Letter)

808a. Obituary: Alfred M. Freedman. Psychiatric Times, June 2011, pg 24.

808b. Obituary: Alfred M. Freedman. Neuropsychopharmacology 2011, 36:2784.

809. Book Review: Nash Boutros, Silvana Galderisi, Oliver Pogarell, Silvana Riggio: Standard Electroencephalography in Clinical Psychiatry: A practical handbook.  Chichester UK: Wiley-Blackwell, 2011. Acta psychiatr scand 2011; 124: 239-40.

810. Book Review. Will I Ever Be the Same Again? Transforming the Face of ECT  (Shock Therapy).J ECT 2011; 27:262-3 [Kellner CH, Fink M.] 

811. Book Review. Hobson, J.Allan. Dream Life: An Experimental Memoir. Science Books & Films 2011; 47(4):186.

2012

812.  Hidden in plain sight: Catatonia in pediatrics. Acta psychiatr scand. 2012: 125:11-12.  [Commentary]

813. Oral History of Neuropsychopharmacology: The First Fifty Years:  Neurophyiology.  Thomas Ban and Max Fink, Editors.  Brentwood TN: ACNP.  Volume 2: 319 pp.

814. Book Review: Bor, Daniel  The Ravenous Brain: How the New Science of Consciousness Explains our Insatiable Search for Meaning.Science Books & Films 2012; 48(9): 243-4.

815. The responsible role for ECT in suicide prevention and treatment. In: A.     Shrivastava, M. Kimball, D.    Lester (Editors): Suicide from a Global Perspective: Risk Assessment and Management.  Chap 14: pg      119-126.

2013

816. Rediscovering  Catatonia: The Biography of a Treatable Syndrome. Acta    psychiatr Scand. 2013; 127: Supplement 441;1-50.[Fink M.]

817. Clinical practice to change with divorce of catatonia and schizophrenia.  J Clin Pychopharmacology 2013; 33(3): 287-88. [Fink M.]

818. Electroconvulsive therapy (ECT) for children, adolescents and adults with developmental disability  and severe mental illness: A call for action. Am J Psychiatry 2013 [Wachtel L. Dhossche D. Fink M,   Jaffe R, Kellner CH, Weeks H, Shorter E.] (Editorial).

819. Are depression's causes biological?  TheNew York Times, September 16, 2013; pg A22. Letter. [with Edward Shorter].

820. Introduction. Electroconvulsive Therapy: A Guide for Professionals and their Patients. Korean Edition; translated by Sangsoo Lee.  Seoul S. Korea: Hana Medical Publishing Co., 233 pp. [Fink M.]

821. The Diagnostic and Statistical Manual of Mental Disorders, Fifth edition, divorces  catatonia from schizophrenia. J Clin Psychopharmacology. 2013; 33(3):1-2.

2014

822. The mechanism of action of ECT.  In: N. Ghaziuddin and G. Walter (Eds.): Electroconvulsive Therapy  in Children and Adolescents 2014.  Chap 2, pp 18-28. New York: Oxford University Press. [Fink  M.]The role of ECT in suicide prevention.  J ECT:30: 5-9.[Fink M, Kellner CH,McCall V.]            

824. What was learned:  Studies by the Consortium for Research in ECT (CORE) 1997-2011. Acta  Psychiatrica  Scand. 129: 417-426. [Fink M.]

825. Thirty years of publication and continuing. [Editorial] J ECT 30: 1-2 [McCall WV, Kellner CH, Fink M.]

826. Celebrating  80 years of inducing brain seizures as psychiatric treatment.  JECT  2014; 30:90. [Fink  M.]

827. Revive flurothyl inhalation treatment in psychiatry?  Psychiatric Times March 19, 2014 [Fink M, Shorter E]

828. The seizure, not electricity, is essential in convulsive therapy: The flurothyl  experience.  J ECT    2014; 30:91-93. [Fink M.]

829. The chemical induction of seizures in psychiatric therapy: Were flurothyl (Indoklon) and pentylenetetrazol (Metrazol) abandoned prematurely? J  Clinical Psychopharmacology. 2014; 34(5):602-7. [Cooper K, Fink M.]

830. Convulsive and non-convulsive treatments in psychiatry.  In: S. Bloch, S. Green, J  Holmes (Eds.): Psychiatry: Past, Present and Prospect.  New York: OxfordUniversity Press, 2014.

831. Obituary. Turan M. Itil.  Neuropsychopharmacology 2014; 39:3133-3134

2015

832. Electroconvulsive therapy versus pharmacotherapy for bipolar depression. Am J Psychiatry 2015; 172(3) 295-6.  [Kellner CH, Fink M.]

833. Reply. [Comment on Wachtel L: Recognition of neuroleptic malignant syndrome and delirious mania as malignant catatoniain an autistic man with prompt relief with ECT.] Acta Psychiatr Scand. 132:320       

834. Seeing the King’s frenzy as catatonia. Acta psychiatr scand 132(6): 500-501. 

835. Book Review. Le Bihan, Denis. Looking Inside the Brain: The Power of Neuroimaging. Princeton U Press. AAAS Science Books & Films

843. Katatonie: Často Sevyskytující Klinický Syndrom Rozpoznatelný a Léčitelný. Catatonia: A Common  Systemic Clinical Syndrome, Recognizable and Treatable. Čes a slov Psychiat 2017; 113(2): 84–93.

844. Does persisting fear sustain catatonia? Acta Psychiatr Scand 2017; Nov;136(5):441-444. [Fink M, Shorter E.]

845. To define melancholia, follow the path of catatonia. Bipolar Dis 2017;19(5);401-2.

846. Electroconvulsive therapy for self-injurious behavior in autism spectrum disorders: Recognizing catatonia is key. Current Opinion. 2017 Dec 18  Epub ahead of print].  [Wachtel LW, Shorter E, Fink M]

847. ECT for catatonia and melancholia: No need for ambivalence. Psychiatric Times 2017; Sep: 16-17F. (Kellner CH, Fink M).

848. Book Review. Electroshock as Means for Social Control. Sadowsky, J.   Electroconvulsive Therapy in America: The Anatomy of a Medical Controversy.JECT 2017; 33:144-5.

2018

849ECT for Self Injurious Behavior in Autism: A New Indication. Psychiatric Times. 56 (2): 6-9.  [Wachtel LE, Kellner CH, Fink M.]

850. Book Review: Electroconvulsive Therapy Revival  in German speaking Countries. JECT 34:70-71.

851.The Madness of Fear: A History of Catatonia. NY: Oxford University Press. [E. Shorter, M. Fink]

 

Internet, Web-Based Articles

1998

W.01 Is catatonia a subtype of schizophrenia? 

http://www.mhsource.com/whatsnew/mfin-cataton.html

W.02 EEG monitoring in ECT: A guide to treatment efficacy.

www.mhsource.com/pt/p980570.html with Richard Abrams

1999

W.03 Pediatric ECT: An update.

http://www.mhsource.com/pt/p990963.html" with Carmel Foley

W.04 Electroshock. An effective treatment for mental illness.

http://www.electroshock.org

W.05a The use of ECT in bipolar disorder (Consumer)

http://www.mhsource.com/bipolar/ect2.html

W.05b The use of ECT in bipolar disorder (Professional)

http://www.mhsource.com/bipolar/ect1.html

2000

W.06 Pediatric ECT . A Review, June 2000.

http://www.electroshock.org/archives/adolescent_ECT_review.htm

W.07 NMS is best treated as catatonia.          

http://www.electroshock.org/archives/NMS-catatonia_review.htm

W.08 ECT 2000.

http://"http://www.longislandpsych.org/arch/ECT/ECTframe.html"

2001

W.09 ECT 2000.

http://www.mdvista.com/library/journal/psychiatry/electroconvulsive_ therapy_2000

W.10 ECT is effective in bipolar disorder.
http://www.BMJ.com/cgi/content/full/321/7272/1302

W.11 Treating bipolar affective disorder. 

http://www.bmj.com/cgi/content/full/322/7282/365/a

W.12 Neuroleptic malignant syndrome and malignant catatonia: Effective treatment,
http://www. mdvista.com/

2002

W.13 Insulin coma therapy. ;

http://www.pbs.org/wgbh/amex/nash/filmmore/ps_ict.html

2005

W.14 The social sources of psychopharmacology.

"http://media.snow.utoronto.ca:8080/ramgen/extra4/BE2005/BE2005-April29-5.rm" 

2009

W.15 ECT in treating status epilepticus.

http://dx.doi.org/10.1016/j.yebeh.2009.06.022

2011

W.16   The race to Patent bio-Tests for Schizophrenia and Depression.

http://www.psychiatrictimes.com/schizophrenia/content/article/

10168/1994367

 

July 19, 2018